GO biological process terms	p-value	GO biological process terms	p-value

Genes up-regulated in erythroblasts

heme biosynthesis	8.3593E-09	tRNA metabolism	4.7686E-04

heme metabolism	4.1178E-08	nitrogen compound metabolism	0.0011

pigment biosynthesis	7.8243E-08	cholesterol biosynthesis	0.0021

porphyrin biosynthesis	8.0158E-08	amino acid activation	0.0022

pigment metabolism	1.8805E-07	tRNA aminoacylation for protein translation	0.0022

porphyrin metabolism	2.5313E-07	tRNA aminoacylation	0.0022

carboxylic acid metabolism	3.5431E-07	electron transport	0.0023

organic acid metabolism	4.0819E-07	amino acid and derivative metabolism	0.0025

secondary metabolism	5.8601E-07	amine metabolism	0.0037

heterocycle metabolism	4.7133E-06	lipid metabolism	0.0037

cellular biosynthesis	6.9372E-06	steroid biosynthesis	0.0041

cofactor metabolism	1.0534E-05	cholesterol metabolism	0.0041

cofactor biosynthesis	1.9914E-05	iron ion homeostasis	0.0042

generation of precursor metabolites and energy	3.9831E-05	sterol biosynthesis	0.0045

cellular metabolism	5.6290E-05	mitotic cell cycle	0.0059

lipid biosynthesis	1.6546E-04	alcohol metabolism	0.0060

cellular lipid metabolism	2.3765E-04	sterol metabolism	0.0061

amino acid metabolism	4.3568E-04

Genes up-regulated in megakaryoblasts

hemostasis	0.0010	positive regulation of cell proliferation	0.0024

endocytosis	0.0011	steroid metabolism	0.0024

cellular lipid metabolism	0.0012	lipid biosynthesis	0.0026

wound healing	0.0014	regulation of receptor mediated endocytosis	0.0034

lipid metabolism	0.0020	localization of cell	0.0049

alcohol metabolism	0.0020	cell motility	0.0049

regulation of body fluids	0.0024	cytoskeleton organization and biogenesis	0.0081

transport	0.0024	cholesterol biosynthesis	0.0089

Genes up-regulated in monoblasts

response to biotic stimulus	6.3071E-15	antimicrobial humoral response	3.1669E-04

immune response	2.8466E-13	detection of stimulus	6.8750E-04

defense response	7.3698E-13	protein kinase cascade	0.0010

response to pest, pathogen or parasite	1.2074E-12	wound healing	0.0014

response to other organism	2.4524E-12	intracellular signaling cascade	0.0017

response to external stimulus	1.0443E-10	positive regulation of cellular process	0.0017

response to stimulus	8.1038E-10	endocytosis	0.0019

response to wounding	1.3630E-09	I-kappaB kinase/NF-kappaB cascade	0.0025

response to stress	2.1560E-08	lymphocyte activation	0.0031

inflammatory response	3.0602E-08	blood coagulation	0.0034

cell communication	5.0323E-07	taxis	0.0035

signal transduction	7.7480E-07	chemotaxis	0.0035

organismal physiological process	8.0044E-07	innate immune response	0.0037

response to pathogen	3.1842E-06	coagulation	0.0038

humoral immune response	3.4723E-05	locomotory behavior	0.0044

detection of biotic stimulus	4.6946E-05	hemostasis	0.0045

response to bacteria	6.7200E-05	carbohydrate metabolism	0.0048

response to pathogenic bacteria	9.7266E-05	cell surface receptor linked signal transduction	0.0059

immune cell activation	1.0815E-04	positive regulation of biological process	0.0064

cell activation	1.2116E-04	macrophage activation	0.0093

humoral defense mechanism (sensu Vertebrata)	1.4837E-04	regulation of body fluids	0.0097

antimicrobial humoral response (sensu Vertebrata)	2.8361E-04

Genes up-regulated in myeloblasts

carboxylic acid metabolism	2.2728E-05	defense response	0.0018

organic acid metabolism	2.3815E-05	response to biotic stimulus	0.0025

cellular biosynthesis	7.1605E-04	immune response	0.0048

biosynthesis	0.0016	positive regulation of cell proliferation	0.0069

GO biological process terms	p-value	GO biological process terms	p-value

response to biotic stimulus	6.3071E-15	antimicrobial humoral response	3.1669E-04

immune response	2.8466E-13	detection of stimulus	6.8750E-04

defense response	7.3698E-13	protein kinase cascade	0.0010

response to pest, pathogen or parasite	1.2074E-12	wound healing	0.0014

response to other organism	2.4524E-12	intracellular signaling cascade	0.0017

response to external stimulus	1.0443E-10	positive regulation of cellular process	0.0017

response to stimulus	8.1038E-10	endocytosis	0.0019

response to wounding	1.3630E-09	I-kappaB kinase/NF-kappaB cascade	0.0025

response to stress	2.1560E-08	lymphocyte activation	0.0031

inflammatory response	3.0602E-08	blood coagulation	0.0034

cell communication	5.0323E-07	taxis	0.0035

signal transduction	7.7480E-07	chemotaxis	0.0035

organismal physiological process	8.0044E-07	innate immune response	0.0037

response to pathogen	3.1842E-06	coagulation	0.0038

humoral immune response	3.4723E-05	locomotory behavior	0.0044

detection of biotic stimulus	4.6946E-05	hemostasis	0.0045

response to bacteria	6.7200E-05	carbohydrate metabolism	0.0048

response to pathogenic bacteria	9.7266E-05	cell surface receptor linked signal transduction	0.0059

immune cell activation	1.0815E-04	positive regulation of biological process	0.0064

cell activation	1.2116E-04	macrophage activation	0.0093

humoral defense mechanism (sensu Vertebrata)	1.4837E-04	regulation of body fluids	0.0097

antimicrobial humoral response (sensu Vertebrata)	2.8361E-04

Genes up-regulated in myeloblasts

carboxylic acid metabolism	2.2728E-05	defense response	0.0018

organic acid metabolism	2.3815E-05	response to biotic stimulus	0.0025

cellular biosynthesis	7.1605E-04	immune response	0.0048

biosynthesis	0.0016	positive regulation of cell proliferation	0.0069


AGRF ID	GenBank Accession	UniGene Cluster	Gene	Fold Change	P Value

H3084H06	BG070211	Mm.25335	EST: Cdc14b: CDC14 cell division cycle 14 homolog B (S. cerevisiae)	+ 3.1	0.044

H3137G08	BG074662	Mm.197274	EST: Moderately similar to GNMSLL retrovirus-related reverse transcriptase homolog – mouse retrotransposon (M. musculus)	+ 3.0	0.046

H3123E03	BG073512	Mm.197252	EST: Weakly similar to TLM MOUSE TLM PROTEIN (M. musculus)	+ 2.9	0.047

H3073G12	BG069200	Mm.328026	EST: Transcribed sequence with moderate similarity to protein ref:NP_083358.1 (M. musculus); RIKEN cDNA 5830411J07	+ 2.5	0.038

H3082G05	AU014577	Not assigned	EST	+ 2.1	0.032


	Mean (SD)

Age	43.7 (9.9) years

Gender	11 males, 12 females

Center-edge angle	33.7 (7.8)°

Alpha angle	73 (9.6)° (all alpha angles were 55° or greater)

Loose bodies visible on radiographs	5 (23.8%)

Loose bodies visible on MRI	14 (66.6%)

Tonnis grade	Grade 0 in 14 patients (66.6%)

Grade 1 in 7 patients (28.5%)

Grade 2 in one (4%)

	Mean (SD)

Tonnis grade	Grade 0 in 14 patients (66.6%)

Grade 1 in 7 patients (28.5%)

Grade 2 in one (4%)


Period	Activity	Who involved

Month 1	Consultation and sensitisation of Kilifi District stakeholders	1. MoH structure: District Medical Officer of Health and District Health Management Team at Kilifi District Hospital. All health facility in-charges working in Kilifi District

2. Provincial administration structures: District Commissioner, Senior District Officer, all chiefs working in Kilifi District

Months 2 to 6	Community entry and sensitisation of stakeholders in sites A, B and C respectively	1. MoH Structure: Dispensary health committees, dispensary staff (facility in-charges, nurses, public health officers, community health extension workers), and community health workers (CHWs)

2. Local administration: District officers, local (assistant) chiefs and village elders

3. Others: primary school head teachers, religious leaders, a local District Stakeholders Forum

Months 8 to 13	Identification and recruitment of 5 to 17 month-old children (n = 600)	CHWs and fieldworkers

Months 15 to 27	Identification and recruitment of 6 to 12 week-old children (n = 304)	CHWs and fieldworkers

From month 8 to date	Follow-up of research participants	Fieldworkers

Continuous feedback to and from community	Fieldworkers and other key gatekeepers

Feedback of results	Involves all of the above, for example, preliminary study results disseminated

Period	Activity	Who involved

Months 2 to 6	Community entry and sensitisation of stakeholders in sites A, B and C respectively	2. Local administration: District officers, local (assistant) chiefs and village elders

3. Others: primary school head teachers, religious leaders, a local District Stakeholders Forum

Months 8 to 13	Identification and recruitment of 5 to 17 month-old children (n = 600)	CHWs and fieldworkers

Months 15 to 27	Identification and recruitment of 6 to 12 week-old children (n = 304)	CHWs and fieldworkers

From month 8 to date	Follow-up of research participants	Fieldworkers

Continuous feedback to and from community	Fieldworkers and other key gatekeepers

Feedback of results	Involves all of the above, for example, preliminary study results disseminated


Item	N	Change +	No change	Change -	p

n	%	n	%	n	%

Habit: days’ sunbathing on the beach	228	73	32.0	112	49.1	43	18.9	0.108

Habit: hours per day	224	75	33.5	101	45.1	48	21.4	0.068

Habit: mid-day sun exposure	222	73	32.9	100	45.0	49	22.1	0.049

Sunburn experienced during the previous summer	227	60	26.4	131	57.7	36	15.9	0.051


Sample	Rapprent (U/mg)	KM (mM)	kcat (min−1)

HRP + GNC-HMS	149	131 ± 9.1	3.6 ± 0.1

GNC-HNC-HMS[b]	151	132 ± 9.3	3.7 ± 0.2


Academic year	Number of students	Verbally noted by student during simulation* N(%)	Written in note after simulation N(%)

Student discovered that acetaminophen was administered n(%)	Student established the dosage of acetaminophen	Student stated that the dose was too high	Student identified medication error in write up	Male	Female

2010-11	114	88 (77)	44 (39)	12 (11)	12 (11)	4 (4)	8 (7)

2011-12	108	44 (41)	49 (45)	9 (8)	9 (8)	8 (7)	1 (1)

2012-13	118	102 (86)	68 (58)	16 (14)	13 (11)	7 (6)	6 (5)

Total	340	234 (69)	161 (47)	37 (11)	34 (10)	19 (6)	15 (4)

Academic year	Number of students	Verbally noted by student during simulation* N(%)

Student discovered that acetaminophen was administered n(%)	Student established the dosage of acetaminophen	Student stated that the dose was too high

2010-11	114	88 (77)	44 (39)	12 (11)

2011-12	108	44 (41)	49 (45)	9 (8)

2012-13	118	102 (86)	68 (58)	16 (14)

Total	340	234 (69)	161 (47)	37 (11)

Written in note after simulation N(%)

Student identified medication error in write up	Male	Female

12 (11)	4 (4)	8 (7)

9 (8)	8 (7)	1 (1)

13 (11)	7 (6)	6 (5)

34 (10)	19 (6)	15 (4)


	Loci	Ref	Var	Gene	Variant type	Novel	Frequency of Mutation

Mismatch Repair

	80149981	A	G	MSH3	nonsynonymous SNV	0	0.60

	80168937	G	A	MSH3	nonsynonymous SNV	0	0.51

	79950724	G	C	MSH3	nonsynonymous SNV	0	0.02

	48023115	T	C	MSH6	synonymous SNV	0	0.14

	48030588	C	T	MSH6	stopgain	0	0.06

Tumor Suppressor

	63410110	T	C	AMER1	synonymous SNV	0	0.08

	63412690	A	C	AMER1	nonsynonymous SNV	0	0.06

	63411276	G	A	AMER1	stopgain	0	0.06

	63411684	G	T	AMER1	nonsynonymous SNV	1	0.06

	112162854	T	C	APC	synonymous SNV	0	0.52

	112164561	G	A	APC	synonymous SNV	0	0.49

	112176325	G	A	APC	synonymous SNV	0	0.49

	112176559	T	G	APC	synonymous SNV	0	0.54

	112177171	G	A	APC	synonymous SNV	0	0.59

	112176756	T	A	APC	nonsynonymous SNV	0	0.57

	112175770	G	A	APC	synonymous SNV	0	0.49

	112164586	C	T	APC	stopgain	0	0.06

	7579472	G	C	TP53	nonsynonymous SNV	0	0.40

	48604664	C	T	SMAD4	nonsynonymous SNV	1	0.08

Oncogenes

	70118935	C	T	SOX9	synonymous SNV	0	0.13

	114912121	G	A	TCF7L2	synonymous SNV	0	0.08

	114910829	A	G	TCF7L2	synonymous SNV	0	0.05

	30732970	G	A	TGFBR2	nonsynonymous SNV	0	0.06

	30713842	C	T	TGFBR2	synonymous SNV	0	0.02

	178916890	C	T	PIK3CA	nonsynonymous SNV	0	0.06

	178952085	A	G	PIK3CA	nonsynonymous SNV	0	0.06

	25368462	C	T	KRAS	synonymous SNV	0	0.67

	Loci	Ref	Var	Gene	Variant type	Novel	Frequency of Mutation

Mismatch Repair

	80149981	A	G	MSH3	nonsynonymous SNV	0	0.60

	80168937	G	A	MSH3	nonsynonymous SNV	0	0.51

	79950724	G	C	MSH3	nonsynonymous SNV	0	0.02

	48023115	T	C	MSH6	synonymous SNV	0	0.14

	48			M		0	0

	Loci	Ref	Var	Gene	Variant type	Novel	Frequency of Mutation

	030588	C	T	SH6	stopgain		.06

Tumor Suppressor

	63410110	T	C	AMER1	synonymous SNV	0	0.08

	63412690	A	C	AMER1	nonsynonymous SNV	0	0.06

	63411276	G	A	AMER1	stopgain	0	0.06

	63411684	G	T	AMER1	nonsynonymous SNV	1	0.06

	112162854	T	C	APC	synonymous SNV	0	0.52

	112164561	G	A	APC	synonymous SNV	0	0.49

	112176325	G	A	APC	synonymous SNV	0	0.49

	112176559	T	G	APC	synonymous SNV	0	0.54

	112177171	G	A	APC	synonymous SNV	0	0.59

	112176756	T	A	APC	nonsynonymous SNV	0	0.57

	112175770	G	A	APC	synonymous SNV	0	0.49

	112164586	C	T	APC	stopgain	0	0.06

	7579472	G	C	TP53	nonsynonymous SNV	0	0.40

	48604664	C	T	SMAD4	nonsynonymous SNV	1	0.08

Oncogenes

	70118935	C	T	SOX9	synonymous SNV	0	0.13

	114912121	G	A	TCF7L2	synonymous SNV	0	0.08

	114910829	A	G	TCF7L2	synonymous SNV	0	0.05

	30732970	G	A	TGFBR2	nonsynonymous SNV	0	0.06

	30713842	C	T	TGFBR2	synonymous SNV	0	0.02

	178916890	C	T	PIK3CA	nonsynonymous SNV	0	0.06

	178952085	A	G	PIK3CA	nonsynonymous SNV	0	0.06

	25368462	C	T	KRAS	synonymous SNV	0	0.67


 	 	P. falciparum ortholog	P. vivax ortholog

Protein description	Ortholog group	PlasmoDB Gene ID	SP prediction	Predicted localization	PlasmoDB Gene ID	SP prediction*

Proline tRNA synthetase	OG4_11662	PFI1240c	+	Apicoplast	PVX_099680 ®	+

 	OG4_10599	PFL0670c	-	Cytosol	PVX_123380	-

Asparagine tRNA synthetase	OG4_44547	PFE0475w	+	Apicoplast	PVX_098040 ®	+

 	OG4_10251	PFB0525w	-	Cytosol	PVX_002940	-

Methionine tRNA synthetase	OG4_47490	PF10_0053	+	Apicoplast	PVX_094445 ®	+

 	OG4_10161	PF10_0340	-	Cytosol	PVX_110980	-

Leucine tRNA synthetase	OG4_11105	PF08_0011	+	Apicoplast	PVX_088945 ®	+

 	OG4_10828	PFF1095w	-	Cytosol	PVX_114255	-

Glutamate tRNA amidotransferase subunit A	OG4_10803	PFD0780w	+	Apicoplast	PVX_089895 ®	+

Initiation Factor-1	OG4_12019	MAL8P1.27	+	Apicoplast	PVX_089095 ®	+

Initiation Factor-3	OG4_14117	PF14_0658	+	Apicoplast	PVX_117015 ®	+

DNA gyrase subunit A	OG4_12828	PFL1120c	+	Apicoplast	PVX_123795 ®	+

 	OG4_10491	PF14_0316	-	Nucleus	PVX_084855	-

DNA gyrase subunit B	OG4_12159	PFL1915w	+	Apicoplast	PVX_100925 ®	+

 	OG4_10746	PF10_0412	-	Nucleus	PVX_111340	-

Ferredoxin	OG4_14702	MAL13P1.95	+	Apicoplast	PVX_122725 ®	+

		P. falciparum ortholog	P. vivax ortholog

Protein description	Ortholog group	PlasmoDB Gene ID	SP prediction	Predicted localization	PlasmoDB Gene ID	SP prediction*

	OG4_10251	PFB0525w	-	Cytosol	PVX_002940	-

Methionine tRNA synthetase	OG4_47490	PF10_0053	+	Apicoplast	PVX_094445 ®	+

	OG4_10161	PF10_0340	-	Cytosol	PVX_110980	-

Leucine tRNA synthetase	OG4_11105	PF08_0011	+	Apicoplast	PVX_088945 ®	+

	OG4_10828	PFF1095w	-	Cytosol	PVX_114255	-

Glutamate tRNA amidotransferase subunit A	OG4_10803	PFD0780w	+	Apicoplast	PVX_089895 ®	+

Initiation Factor-1	OG4_12019	MAL8P1.27	+	Apicoplast	PVX_089095 ®	+

Initiation Factor-3	OG4_14117	PF14_0658	+	Apicoplast	PVX_117015 ®	+

DNA gyrase subunit A	OG4_12828	PFL1120c	+	Apicoplast	PVX_123795 ®	+

	OG4_10491	PF14_0316	-	Nucleus	PVX_084855	-

DNA gyrase subunit B	OG4_12159	PFL1915w	+	Apicoplast	PVX_100925 ®	+

	OG4_10746	PF10_0412	-	Nucleus	PVX_111340	-

Ferredoxin	OG4_14702	MAL13P1.95	+	Apicoplast	PVX_122725 ®	+


Number of patients	Total

 	n = 2,270

Age, years (SD)	61.7 (17.0)

Sex, male (%)	1,277 (56.3)

Height, metres (SD)	1.68 (0.11)

Weight, kg (SD)	78.1 (26.0)

BMI, mean (SD)	27.6 (8.3)

BMI, n (%)

<24	1,039 (45.9)

25-29	594 (26.2)

30-40	463 (20.4)

>40	169 (7.5)

Admission type

Medical, n (%)	2,270 (100)

Surgical	0

ICU admission diagnosis, n (%)

Aspiration pneumonia	330 (14.5)

Bacterial/viral pneumonia	911 (40.1)

Sepsis (other than urinary tract)	859 (37.8)

Sepsis of urinary tract origin	170 (7.5)

APACHE II score, mean (SD)	23.9 (7.9)

Days from hospital admission to ICU admission (hours), median [IQR]	6.55 [0.08, 65.08]

Days from hospital admission to ICU admission, n (%)

[0–1] day	1,437 (63.4)

[1-3] days	303 (13.4)

>3 days	527 (23.3)

Length of ICU stay (days), median [IQR]	11.5 [6.9-21.4]

Length of hospital stay (days), median [IQR]	23.8 [13.8-48.5]

Length of mechanical ventilation (days), median [IQR]	8.4 [4.6-19.2]

Ventilator-free days, median [IQR]	46.4 [4.0-55.0]

Mortality (60 day),%	30.5

Number of patients

Age, years (SD)

Sex, male (%)

Height, metres (SD)

Weight, kg (SD)

BMI, mean (SD)

BMI, n (%)

<24

25-29

30-40

>40

Admission type

Medical, n (%)

Surgical

ICU admission diagnosis, n (%)

Aspiration pneumonia

Bacterial/viral pneumonia

Sepsis (other than urinary tract)

Sepsis of urinary tract origin

APACHE II score, mean (SD)

Days from hospital admission to ICU admission (hours), median [IQR]

Days from hospital admission to ICU admission, n (%)

[0–1] day

[1-3] days

>3 days

Length of ICU stay (days), median [IQR]

Length of hospital stay (days), median [IQR]

Length of mechanical ventilation (days), median [IQR]

Ventilator-free days, median [IQR]

Mortality (60 day),%


	Group A (n = 45)	Group B (n = 31)		Group C (n = 18)

	Stool		Duodenal fluid		Stool

	Kato-Katz	Filtration	Kato-Katz	Kato-Katz

Helminth species	Positive/examined (%)	Intensity (epg)	Positive/examined (%)	Intensityb	Positive/examined (%)	Intensity (epg)	Positive/examined (%)	Intensity (epg)

		Median (range)		Median (range)		Median (range)		Median (range)

Opisthorchis viverrini	45/45 (100)	900 (60–13,710)	19/32 (59.4)	24 (1–7140)	15/29 (52.7)	40 (24–56)	9/18 (50.0)	24 (24–40)

Hookworma	18/45 (40.0)	180 (30–2940)	4/32 (12.5)	13 (5–27)	6/29 (20.7)	24 (24–72)	0/18 (0)	n.a.

T. trichiura	4/45 (8.9)	n.d.	0/32 (0)	n.a.	0/29 (0)	n.d.	0/18 (0)	n.a.

Taenia spp.a	7/45 (15.6)	n.d.	0/32 (0)	n.a.	0/29/0)	n.a.	0/18 (0)	n.a.

Trichostrongylus spp.b	0/45 (0)	n.a.	0/32 (0)	n.a.	3/29 (10.3)	n.d.	2/18 (11.1)	n.d.


OPEN APPENDECTOMY	Nr. UNITS	TOTAL

2/0 silk suture	3	0.4 €

2/0 braided absorbable suture	2	4.3 €

Suction device	1	2.3 €

TOTAL	 	7 €

LAPAROSCOPIC APPENDECTOMY

Hasson Trocar	1	37 €

5 mm Trocar	2	70 €

Endoclinch	1	75 €

Lap. Irrigation/suction device	1s	70 €

Biosyn® 3/0	2	4.3 €

1-Ti-Cron® suture	1	3 €

TOTAL	 	259.3 €

DIFFERENTIAL	 	+ 252.3 €

OPEN APPENDECTOMY	Nr. UNITS	TOTAL

Biosyn® 3/0	2	4.3 €

1-Ti-Cron® suture	1	3 €

TOTAL		259.3 €

DIFFERENTIAL		+ 252.3 €


Age

15–19 years

20–24 years

25–29 years

30–34 years

35–39 years

40–44 years

45–49 years

Wealth Index

Poorest

Poor

Middle

Rich

Richest

Highest Education

No Education

Primary

Secondary

Higher

Region

Barisal

Chittagong

Dhaka

Khulna

Rajshahi

Rangpur

Sylhet

Type of Residence

Urban

Rural

Sex of Household Head

Male

Female


Social variable	Nonpregnant women	Pregnant women

Age (years)	29.250 ± 2.314	28.333 ± 1.971

Ethnicity	Han	Han

Occupation

 Housewife	0	3

 Employee	20	27

Level of education

 <Technical	6	10

 Bachelor	9	13

 Master	5	7

Economic status	Regular	Regular

Social variable	Nonpregnant women	Pregnant women

<Technical	6	10

Bachelor	9	13

Master	5	7

Economic status	Regular	Regular


Diet ingredients, % (DM basis)	Ratio

Corn stalk pellets	60.0

Corn	24.8

Soybean meal	10.4

Wheat bran	3.2

Sodium chloride	0.4

Calcium hydrophosphate	0.8

Premixa	0.4

Nutrient composition (DM basis)

Dry matter, %	93.56

Digestible energy, MJ/kg	8.13

Crude protein, %	10.39

Ether extract, %	8.15

Neutral detergent fiber, %	22.79

Acid detergent fiber, %	16.0

Vitamin E, IU/kg	5.08

Diet ingredients, % (DM basis)	Ratio

ent composition (DM basis)

Dry matter, %	93.56

Digestible energy, MJ/kg	8.13

Crude protein, %	10.39

Ether extract, %	8.15

Neutral detergent fiber, %	22.79

Acid detergent fiber, %	16.0

Vitamin E, IU/kg	5.08


Comp-ound	Docking Score	Residue involv-ed in hydrogen bonds	Residues involv-ed in π-π intera-ctions

9	-6.76	Asp-168	Lys 53, Arg 67

10	-6.70	Asp-168	Arg 67

11	-4.30	Asp-168	His 148, Arg 67

12	-5.29	Asp-168	-

13	-4.52	Asp-168	His 174, Arg 67

14	-4.69	Met-109	Phe 169

15	-5.19	Asp-168	Arg 67

Comp-ound	Docking Score	Residue involv-ed in hydrogen bonds	Residues involv-ed in π-π intera-ctions

10	-6.70	Asp-168	Arg 67

11	-4.30	Asp-168	His 148, Arg 67

12	-5.29	Asp-168	-

13	-4.52	Asp-168	His 174, Arg 67

14	-4.69	Met-109	Phe 169

15	-5.19	Asp-168	Arg 67


	Positive influenza A	Positive influenza B	Negative samples

Seasonal H1N1	2009 pandemic H1N1	H3N2	H5N1

RT-qPCR	14	39	29	2	69	80

Multiplex DPO PCR	13	25	16	2	43	134

Positive Concordant Percentage	56 (66.67%, 56/84)	43(62.32%, 43/69)	____

	Positive influenza A

Seasonal H1N1

RT-qPCR	14

Multiplex DPO PCR	13

Positive Concordant Percentage	56 (66.67%, 56/84)

Positive influenza A	Positive influenza B	Negative samples

2009 pandemic H1N1	H3N2	H5N1

39	29	2	69	80

25	16	2	43	134

56 (66.67%, 56/84)	43(62.32%, 43/69)	____


Animal name	Genotype	Sex	Age (m)	Brain weight (g)	CA1 thickness (μm)	Cortex thickness (μm)	Nf	Nn

15	Tau	M	8–9	14	6	0	10	18

AN22	Tau	M	7–8	NA	28	550	20	10

AN23	Tau	M	7–8	0.198	24	550	7	10

AN24	Tau	F	7–8	0.232	27	550	14	14

AN25	Tau	M	7–8	0.226	26	NA	29	27

						Total	333	327


Wealth variable	Response options	Crude score	Rescaled crude score	Assigned weight	Weighted score

Main roof material	Cement/concrete	4	1.00	5	5.00

Corrugated iron	3	0.67	 	3.35

Wood planks/wood	2	0.33	 	1.65

Thatch / leaf/reed/bamboo	1	0.00	 	0.00

Type of toilet facility	Flush to septic tank/sewer system/pit latrine	6	1.00	4	4.00

Ventilated improved pit latrine (VIP)	5	0.80	 	3.20

Pit latrine with slab	4	0.60	 	2.40

Pit latrine without slab / open pit	3	0.40	 	1.60

Composting toilet	2	0.20	 	0.80

No facility / bush / field	1	0.00	 	0.00

Educational attainment	Higher	6	1.00	3	3.00

Complete secondary	5	0.80	 	2.40

Incomplete secondary	4	0.60	 	1.80

Complete primary	3	0.40	 	1.20

Incomplete primary	2	0.20	 	0.60

No education	1	0.00	 	0.00

Household owns table	Yes	2	1.00	2	2.00

No	1	0.00	 	0.00

Household has radio	Yes	2	1.00	1	1.00

No	1	0.00	 	0.00

Wealth variable	Response options	Crude score	Rescaled crude score	Assigned weight

Main roof material	Cement/concrete	4	1.00	5

Corrugated iron	3	0.67

Wood planks/wood	2	0.33

Thatch / leaf/reed/bamboo	1	0.00

Type of toilet facility	Flush to septic tank/sewer system/pit latrine	6	1.00	4

Ventilated improved pit latrine (VIP)	5	0.80

Pit latrine with slab	4	0.60

Pit latrine without slab / open pit	3	0.40

Composting toilet	2	0.20

No facility / bush / field	1	0.00

Educational attainment	Higher	6	1.00	3

Complete secondary	5	0.80

Incomplete secondary	4	0.60

Complete primary	3	0.40

Incomplete primary	2	0.20

No education	1	0.00

Household owns table	Yes	2	1.00	2

No	1	0.00

Household has radio	Yes	2	1.00	1

No	1	0.00


Number	Raw CW (g)	Water Added (mL)	Mixing Condition	Final Liquid Volume (mL)	Recovery (g sugars/kg raw CW)

1	250	250	Mixer	170	19.7

2	150	250	Mixer	250	29.7

3	250	250	Shaking at 120 rpm (15 min)	250	24.8

4	150	250	Shaking at 120 rpm (15 min)	250	30.3


Operation	Duration (ms)

Conceptual preparation (from picture onset to selecting the target concept)	175

Lemma retrievalForm encoding:	75

Phonological code retrieval	80

Syllabification	125

Phonetic encoding (till initiation of articulation)	145

Total	600


Excluded species	Reasons for exclusion

Baissopsyche pura	Forewing venation not complete, key characters missing

Mesopsyche ordinata	Forewing width/length ratio at 0.48 much higher than that of all others (with typical ratio between 0.30 and 0.35 and two outliers at 0.27 and 0.38)

Mesopsyche justa	Base of forewing missing for holotype; inconsistent venation among holotype and paratypes.

Mesopsyche gentica	Base of forewing missing

Mesopsyche tortiva	Incomplete forewing and base of hind wing missing

Mesopsyche incompleta	Incomplete fore- and hind wings

Mesopsyche javorskii	Hind wing only

Mesopsyche tongchuanensis	Incomplete forewing only

Mesopanorpodes wianamattensis	Anal area of forewing missing

Permopsyche robustus	Incomplete forewing only

Mesoses optata	Incomplete forewing only

Mesoses magna	Incomplete forewing only

Mesoses gayndah	Incomplete forewing only

Ptychopteropsis mirabilis	Incomplete forewing only

Turanopsyche venosa	Incomplete hind wing only

Ferghanopsyche rotundata	Incomplete forewing only

Excluded species

Baissopsyche pura

Mesopsyche ordinata

Mesopsyche justa

Mesopsyche gentica

Mesopsyche tortiva

Mesopsyche incompleta

Mesopsyche javorskii

Mesopsyche tongchuanensis

Mesopanorpodes wianamattensis

Permopsyche robustus

Mesoses optata

Mesoses magna

Mesoses gayndah

Ptychopteropsis mirabilis

Turanopsyche venosa

Ferghanopsyche rotundata

Reasons for exclusion

Forewing venation not complete, key characters missing

Forewing width/length ratio at 0.48 much higher than that of all others (with typical ratio between 0.30 and 0.35 and two outliers at 0.27 and 0.38)

Base of forewing missing for holotype; inconsistent venation among holotype and paratypes.

Base of forewing missing

Incomplete forewing and base of hind wing missing

Incomplete fore- and hind wings

Hind wing only

Incomplete forewing only

Anal area of forewing missing

Incomplete forewing only

Incomplete forewing only

Incomplete forewing only

Incomplete forewing only

Incomplete forewing only

Incomplete hind wing only

Incomplete forewing only


 	Cryptography authentication	Biometrics recognition

Authentication method	Digital	Analog

Authentication rule	Without error tolerance	With error tolerance

Data processing	Data is disordered	Data is processed but not disordered

Adoption of cryptography technique	Data can be encrypted and signed	Data cannot be encrypted or signed

Authentication method

Authentication rule

Data processing

Adoption of cryptography technique

Cryptography authentication	Biometrics recognition

Digital	Analog

Without error tolerance	With error tolerance

Data is disordered	Data is processed but not disordered

Data can be encrypted and signed	Data cannot be encrypted or signed


Case	Removal of catheter	Antifungal treatment	Outcome	References

1	Yes	AmB (cumulative dose, 0.3 g)	Switching to permanent hemodialysis	[18]

2	Yes	AmB (cumulative dose, 2 g)	Cured	[20]

3	Yes	AmB + 5-FC	Died	[20]

4	Yes	AmB (cumulative dose, 1.4 g) + 5-FC (cumulative dose, 55 g)	Switching to permanent hemodialysis	[19]

5	Yes	MCZ × 3 days + AmB (cumulative dose, 0.5 g)	Cured	[16]

6	Yes	KCZ 400 mg/day × 2 days + FCZ 400 mg/day × 5 days	Cured	[21]

7	Yes	AmB 0.5 mg/kg/day × 6 weeks +5-FC × 4 weeks	Switching to permanent hemodialysis	[22]

8	Yes	(FCZ 200 mg/day + CPF 50 mg/day) × 5 days + AmB liposomal 400 mg/day × 7 days	Switching to permanent hemodialysis	[14]

9	Yes	FCZ200 mg/day × 6 days + AmB 0.5 mg/kg/day × 4 weeks	Switching to permanent hemodialysis	[15]

10	Yes	VCZ 500 mg × 8 days	Cured	[13]

11	No	AmB (cumulative dose, 2.5 g) + 5-FC 50 mg/kg × 6 weeks	Cured	[23]

12	No	AmB (cumulative dose, 1.9 g)	Cured	[17]

13	Yes	AmB 0.5 mg/kg/day × 6 weeks	Died	[24]

14	ND	ND	Died	[27]

15	No	(AmB + 5-FC) × 9 days + FCZ × 24 weeks	Cured	[26]

16	No	VCZ 400 mg/d × 10 days + AmB 100 mg/day × 4 days + 	Cured	[25]

17	No	(VCZ 0.4 g/day + 5-FC 4 g/day) × 2 weeks	Cured	This study

18	No	(AmB 30 mg/days + 5-FC 4.5 g/day) × 4 weeks	Cured	This study

Case	Removal of catheter	Antifungal treatment	Outcome	References

1	Yes	AmB (cumulative dose, 0.3 g)	Switching to permanent hemodialysis	[18]

2	Yes	AmB (cumulative dose, 2 g)	Cured	[20]

3	Yes	AmB + 5-FC	Died	[20]

4	Yes	AmB (cumulative dose, 1.4 g) + 5-FC (cumulative dose, 55 g)	Switching to permanent hemodialysis	[19]

5	Yes	MCZ × 3 days + AmB (cumulative dose, 0.5 g)	Cured	[16]

6	Yes	KCZ 400 mg/day × 2 days + FCZ 400 mg/day × 5 days	Cured	[21]

7	Yes	AmB 0.5 mg/kg/day × 6 weeks +5-FC × 4 weeks	Switching to permanent hemodialysis	[22]

8	Yes	(FCZ 200 mg/day + CPF 50 mg/day) × 5 days + AmB liposomal 400 mg/day × 7 days	Switching to permanent hemodialysis	[14]

9	Ye	FCZ200 mg/day × 6 days + A	Switching to permanent hemod	[15

Case	Removal of catheter	Antifungal treatment	Outcome	References

	s	mB 0.5 mg/kg/day × 4 weeks	ialysis	]

10	Yes	VCZ 500 mg × 8 days	Cured	[13]

11	No	AmB (cumulative dose, 2.5 g) + 5-FC 50 mg/kg × 6 weeks	Cured	[23]

12	No	AmB (cumulative dose, 1.9 g)	Cured	[17]

13	Yes	AmB 0.5 mg/kg/day × 6 weeks	Died	[24]

14	ND	ND	Died	[27]

15	No	(AmB + 5-FC) × 9 days + FCZ × 24 weeks	Cured	[26]

16	No	VCZ 400 mg/d × 10 days + AmB 100 mg/day × 4 days +	Cured	[25]

17	No	(VCZ 0.4 g/day + 5-FC 4 g/day) × 2 weeks	Cured	This study

18	No	(AmB 30 mg/days + 5-FC 4.5 g/day) × 4 weeks	Cured	This study


CESD-10 score category	n	Total tremor score	ETEA score	Number (%) who had been prescribed medication for tremor

0–9 (no or minimal depressive symptoms)	47	19.6 ± 6.2	19.9 ± 16.4	28 (59.6)

10–19 (moderate depressive symptoms)	37	22.1 ± 5.8	28.4 ± 16.4	24 (64.9)

≥20 (severe depressive symptoms)	7	19.0 ± 2.0	31.4 ± 17.6	7 (100)

		p = 0.36a	p = 0.01b

CESD-10 score category

0–9 (no or minimal depressive symptoms)

10–19 (moderate depressive symptoms)

≥20 (severe depressive symptoms)


Groupsa	Immunization time

1st	2nd	3rd	4th

PBS	100 μl	100 μl	100 μl	100 μl

pEGFPb	100 μg	100 μg	100 μg	100 μg

pGRA4c	100 μg	100 μg	100 μg	100 μg

peptided	100 μg	100 μg	100 μg	100 μg

peptide/DNA	100 μg peptide	100 μg peptide	100 μg pGRA4	100 μg pGRA4

DNA/peptide	100 μg pGRA4	100 μg pGRA4	100 μg peptide	100 μg peptide

sa	1st	2nd	rd	4th

PBS	100 μl	100 μl	100 μl	100 μl

pEGFPb	100 μg	100 μg	100 μg	100 μg

pGRA4c	100 μg	100 μg	100 μg	100 μg

peptided	100 μg	100 μg	100 μg	100 μg

peptide/DNA	100 μg peptide	100 μg peptide	100 μg pGRA4	100 μg pGRA4

DNA/peptide	100 μg pGRA4	100 μg pGRA4	100 μg peptide	100 μg peptide


Variables	 Frequency	 Percent

Number of pregnancies

 1	161	29.7

 2-3	276	50.9

 4+	105	19.4

Gestational age

 ≤16	10	 1.9

 17–24	134	24.7

 25–35	333	61.4

 ≥36	65	12.0

Antenatal visit

 Yes	312	57.6

 No	230	42.4

Number of ANC visit (n = 312)

 1	122	39.1

 2-3	176	56.4

 4+	14	 4.5

Received information from health care providers

 On HIV

Yes	346	63.8

No	196	36.2

 On antenatal care

Yes	304	56.1

No	238	43.9

 On MTCT

Yes	284	52.4

No	258	47.6

 On infant feeding

Yes 	181	33.4

No 	361	66.6

Comprehensive knowledge of HIV/AIDS

 Yes 	346 	63.8

 No	196	36.2

Heard of PITC

 Yes 	345 	63.7

 No	197	36.3

Heard about MTCT

 Yes 	458 	84.5

 No	84	15.5

Know the means of transmission on MTCT (n = 458)

 During pregnancy	309 	67.5

 During labor/delivery	324 	70.7

 During breast feeding	251 	54.8

Exact timing of MTCT answered by women

 None	84	 15.5

 One	130 	24.0

 Two	225 	41.5

 Three	103 	19.0

Variables	Frequency	Percent

Number of pregnancies

1	161	29.7

2-3	276	50.9

4+	105	19.4

Gestational age

≤16	10	1.9

17–24	134	24.7

25–35	333	61.4

≥36	65	12.0

Antenatal visit

Yes	312	57.6

No	230	42.4

Number of ANC visit (n = 312)

1	122	39.1

2-3	176	56.4

4+	14	4.5

Received information from health care providers

On HIV

Yes	346	63.8

No	196	36.2

On antenatal care

Yes	304	56.1

No	238	43.9

On MTCT

Yes	284	52.4

No	258	47.6

On infant feeding

Yes	181	33.4

No	361	66.6

Comprehensive knowledge of HIV/AIDS

Yes	346	63.8

No	196	36.2

Heard of PITC

Yes	345	63.7

No		3

	197	6.3

Heard about MTCT

Yes	458	84.5

No	84	15.5

Know the means of transmission on MTCT (n = 458)

During pregnancy	309	67.5

During labor/delivery	324	70.7

During breast feeding	251	54.8

Exact timing of MTCT answered by women

None	84	15.5

One	130	24.0

Two	225	41.5

Three	103	19.0


 	No. of contigs with hits	No. of unique accessions	No. of unique protein hits

Zebrafish RefSeq	87,931	19,711	19,711

Uniprot/Swiss-Prot	80,012	26,396	17,669

Total	94,476	-	25,144

	No. of contigs with hits	No. of unique accessions	No. of unique protein hits

Total	94,476	-	25,144


Parameters	Results

Weight (g)	24.9±3.1

Peak CSA [ mm2]

Cartesian Measurement	0.75±0.05

Radial Triggered Measurement	0.75±0.04

Retrospective Measurement	0.73±0.04

Peak volume flow [ cm3/s]

Cartesian Measurement	0.27±0.04

Radial Triggered Measurement	0.28±0.03

Retrospective Measurement	0.28±0.04

PWV [m/s]

Cartesian Measurement	2.4±0.2

Radial Triggered Measurement	2.3±0.2

Retrospective Measurement	2.3±0.2


Chiropractor ID	Number of diagnoses coded	Agreement on *rubric level(%)	Agreement on **term level(%)

1	9	89	67

2	20	15	10

3	12	92	50

4	15	60	0

5	14	29	29

6	9	67	56

7	14	29	7

8	10	100	100

9	16	44	31

10	11	82	73

11	10	100	10

12	11	27	18

13	12	0	0

14	4	75	0

Overall agreement %		52	35

Agreement expected by chance		17	6

Overall agreement (Cohen’s Kappa)	Total number of codes: 167	0.4 (95% CI 0.3-0.7)***	0.3 (95% CI 0.2-0.5)***

Chiropractor ID

1

2

3

4

5

6

7

8

9

10

11

12

13

14

Overall agreement %

Agreement expected by chance

Overall agreement (Cohen’s Kappa)


Measure	Sample size	Mean score (SD)

Adverse childhood experience (ACE) score	n = 67	1.93 (2.45)

ACE z-score	n = 67	0.053 (0.94)

ACE (range)	n = 67	0.00–10.00

Measure	Sample size	Mean score (SD)

Adverse childhood experience (ACE) score	n = 67	1.93 (2.45)

ACE z-	n = 	0.053 (0.94)


Prevalence (%)	Men	Women	Total

Diabetes	14.0	10.0	11.6

Dyslipidemia	27.4	34.8	31.8

Hypertension	30.2	36.2	33.7

Smoking	12.6	7.9	9.8

Obesity	17.3	21.5	19.8

Prevalence (%)	Men	Women

Diabetes	14.0	10.0

Dyslipidemia	27.4	34.8

Hypertension	30.2	36.2

Smoking	12.6	7.9

Obesity	17.3	21.5


Demographics	Baseline	Follow-up

Male, n	19 (61%)

Mean age + −SD, years 70.2 (SD 11.7)

< 9 years of education	5 (16%)

Stroke subtype

 Cerebral infarction	29 (94%)

 TIA	2 (6%)

Risk factors, n

 Hypertension	20 (65%)

 Hyperlipideamia	23 (74%)

 Diabetes	6 (19%)

 Current smoking	7 (23%)

 Atrial fibrillation	3 (10%)

 BMI	18 (58%)

TOAST classification, n

 Large-vessel disease	2 (7%)

 Cardio-embolic disease	2 (6%)

 Small vessel disease	17 (55%)

 Stroke of undetermined aetiology	10 (32%)

OCSP classification, n

 TACI	0

 PACI	13 (42%)

 LACI	15 (48%)

 POCI	3 (10%)

Assessments

 NIHSS, day 1, mean (IQR)	3.06 (1.0-4.0)	0.58 (0.0-1.0)

 BI, mean(IQR)	18.5 (19.5-20.0)	19.48 (20.0-20.0)

 mRS, mean (IQR)	1.35 (0.0-3.0)	1.06 (1.0-1.0)

 Total TAU, mean (IQR)		363 (227–382)

 Apoɛ4	9 (29%)

 TMT A (seconds) (SD)	86.0 (±97.0)	61.6 (±48.4)

 MMSE (points) (SD)	26.0 (±3.8)	26.7 (±3.9)

 10 word test (words)	20.1 (±6.8)	24.5 (±6.1)

 Ventricular volume (mm^3)(SD)	60,796 (±17,339)	60,334 (±25,118)

 Global brain volume(mm^3) (SD)	1,404,660 (±63,160)	1,368,194 (±142,856)


Dimension

UNIT LEVEL AGGREGATION

Leadership

Culture

Evaluation

Social Capital

Formal Interactions

Informal Interactions

Structural and Electronic Resources

OS-staff

OS-space

OS-time

NURSING HOME LEVEL AGGREGATION

Leadership

Culture

Evaluation

Social Capital

Formal Interactions

Informal Interactions

Structural and Electronic Resources

OS-staff

OS-space

OS-time


Sample	N (mmol/g)	C (mmol/g)	Molar ratio of C/N	CO2 adsorption capacity (mmol/g)	Amine efficiency

25 °C	30 °C	50 °C	75 °C	25 °C	30 °C	50 °C	75 °C

APS/LDHs	3.89	25.62	6.58	1.55	2.05	2.09	1.86	0.40	0.53	0.54	0.48

Sample	N (mmol/g)	C (mmol/g)	Molar ratio of C/N	CO2 adsorption capacity (mmol/g)	Amine efficiency

25 °C	30 °C	50 °C	75 °C	25 °C	30 °C	50 °C	75 °C

	3.	2	6.			2.	1.


Gene	ENSEMBL ID	ENSEMBL description

Acot7	ENSMUSG00000028937	acyl-CoA thioesterase 7 [Acc:MGI:1917275]

Ankrd13d	ENSMUSG00000005986	ankyrin repeat domain 13 family, member D [Acc:MGI:1915673]

Aplp1	ENSMUSG00000006651	amyloid beta (A4) precursor-like protein 1 [Acc:MGI:88046]

Atp1a3	ENSMUSG00000040907	ATPase, Na+/K+ transporting, alpha 3 polypeptide [Acc:MGI:88107]

Atp6v1a	ENSMUSG00000052459	ATPase, H+ transporting, lysosomal V1 subunit A [Acc:MGI:1201780]

Atp6v1d	ENSMUSG00000021114	ATPase, H+ transporting, lysosomal V1 subunit D [Acc:MGI:1921084]

Calm3	ENSMUSG00000019370	calmodulin 3 [Acc:MGI:103249]

Cdh13	ENSMUSG00000031841	cadherin 13 [Acc:MGI:99551]

Cyfip2	ENSMUSG00000020340	cytoplasmic FMR1 interacting protein 2 [Acc:MGI:1924134]

Dos	ENSMUSG00000035640	downstream of Stk11 [Acc:MGI:1354170]

Dusp26	ENSMUSG00000039661	dual specificity phosphatase 26 (putative) [Acc:MGI:1914209]

Gprasp1	ENSMUSG00000043384	G protein-coupled receptor associated sorting protein 1 [Acc:MGI:1917418]

Gria1	ENSMUSG00000020524	glutamate receptor, ionotropic, AMPA1 (alpha 1) [Acc:MGI:95808]

Grina	ENSMUSG00000022564	glutamate receptor, ionotropic, N-methyl D-asparate-associated protein 1 [Acc:MGI:1913418]

Hdac11	ENSMUSG00000034245	histone deacetylase 11 [Acc:MGI:2385252]

Kifap3	ENSMUSG00000026585	kinesin-associated protein 3 [Acc:MGI:107566]

Kns2	ENSMUSG00000021288	kinesin 2 [Acc:MGI:107978]

Ndrg4	ENSMUSG00000036564	N-myc downstream regulated gene 4 [Acc:MGI:2384590]

Pcdh17	ENSMUSG00000035566	protocadherin 17 [Acc:MGI:2684924]

Pfkm	ENSMUSG00000033065	phosphofructokinase, muscle [Acc:MGI:97548]

Phactr1	ENSMUSG00000054728	phosphatase and actin regulator 1 [Acc:MGI:2659021]

Pja2	ENSMUSG00000024083	praja 2, RING-H2 motif containing [Acc:MGI:2159342]

Ppp2r2c	ENSMUSG00000029120	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform [Acc:MGI:2442660]

Prkacb	ENSMUSG00000005034	protein kinase, cAMP dependent, catalytic, beta [Acc:MGI:97594]

Rogdi	ENSMUSG00000022540	rogdi homolog (Drosophila) [Acc:MGI:1913299]

Rusc1	ENSMUSG00000041263	RUN and SH3 domain containing 1 [Acc:MGI:1919546]

Scamp5	ENSMUSG00000040722	secretory carrier membrane protein 5 [Acc:MGI:1928948]

Slc25a4	ENSMUSG00000031633	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 [Acc:MGI:1353495]

Stx1b2	ENSMUSG00000030806	syntaxin 1B2 [Acc:MGI:1930705]

Sult4a1	ENSMUSG00000018865	sulfotransferase family 4A, member 1 [Acc:MGI:1888971]

Sv2a	ENSMUSG00000038486	synaptic vesicle glycoprotein 2 a [Acc:MGI:1927139]

Syngr3	ENSMUSG00000007021	synaptogyrin 3 [Acc:MGI:1341881]

Tspyl4	ENSMUSG00000039485	TSPY-like 4 [Acc:MGI:106393]

Vamp2	ENSMUSG00000020894	vesicle-associated membrane protein 2 [Acc:MGI:1313277]

Wbp2	ENSMUSG00000034341	WW domain binding protein 2 [Acc:MGI:104709]

Wsb2	ENSMUSG00000029364	WD repeat and SOCS box-containing 2 [Acc:MGI:2144041]

0710005I19Rik	ENSMUSG00000041141	RIKEN cDNA 0710005I19 gene [Acc:MGI:1918941]

2900002G04Rik	ENSMUSG00000041020	RIKEN cDNA 2900002G04 gene [Acc:MGI:1917474]

2900011O08Rik	ENSMUSG00000044117	RIKEN cDNA 2900011O08 gene [Acc:MGI:1914504]

5330410G16Rik	ENSMUSG00000035964	RIKEN cDNA 5330410G16 gene [Acc:MGI:1915187]

A030009H04Rik	ENSMUSG00000043419	RIKEN cDNA A030009H04 gene [Acc:MGI:1915359]

Gene	ENSEMBL ID	ENSEMBL description

Acot7	ENSMUSG00000028937	acyl-CoA thioesterase 7 [Acc:MGI:1917275]

Ankrd13d	ENSMUSG00000005986	ankyrin repeat domain 13 family, member D [Acc:MGI:1915673]

Aplp1	ENSMUSG00000006651	amyloid beta (A4) precursor-like protein 1 [Acc:MGI:88046]

Atp1a3	ENSMUSG00000040907	ATPase, Na+/K+ transporting, alpha 3 polypeptide [Acc:MGI:88107]

Atp6v1a	ENSMUSG00000052459	ATPase, H+ transporting, lysosomal V1 subunit A [Acc:MGI:1201780]

Atp6v1d	ENSMUSG00000021114	ATPase, H+ transporting, lysosomal V1 subunit D [Acc:MGI:1921084]

Calm3	ENSMUSG00000019370	calmodulin 3 [Acc:MGI:103249]

Cdh13	ENSMUSG00000031841	cadherin 13 [Acc:MGI:99551]

Cyfip2	ENSMUSG00000020340	cytoplasmic FMR1 interacting protein 2 [Acc:MGI:1924134]

Dos	ENSMUSG00000035640	downstream of Stk11 [Acc:MGI:1354170]

Dusp26	ENSMUSG00000039661	dual specificity phosphatase 26 (putative) [Acc:MGI:1914209]

Gprasp1	ENSMUSG00000043384	G protein-coupled receptor associated sorting protein 1 [Acc:MGI:1917418]

Gria1	ENSMUSG00000020524	glutamate receptor, ionotropic, AMPA1 (alpha 1) [Acc:MGI:95808]

Grina	ENSMUSG00000022564	glutamate receptor, ionotropic, N-methyl D-asparate-associated protein 1 [Acc:MGI:1913418]

Hdac11	ENSMUSG00000034245	histone deacetylase 11 [Acc:MGI:2385252]

Kifap3	ENSMUSG00000026585	kinesin-associated protein 3 [Acc:MGI:107566]

Kns2	ENSMUSG00000021288	kinesin 2 [Acc:MGI:107978]

Ndrg4	ENSMUSG00000036564	N-myc downstream regulated gene 4 [Acc:MGI:2384590]

Pcdh17	ENSMUSG00000035566	protocadherin 17 [Acc:MGI:2684924]

Pfkm	ENSMUSG00000033065	phosphofructokinase, muscle [Acc:MGI:97548]

Ph	ENSMUSG	phosphatase and actin

Gene	ENSEMBL ID	ENSEMBL description

actr1	00000054728	regulator 1 [Acc:MGI:2659021]

Pja2	ENSMUSG00000024083	praja 2, RING-H2 motif containing [Acc:MGI:2159342]

Ppp2r2c	ENSMUSG00000029120	protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), gamma isoform [Acc:MGI:2442660]

Prkacb	ENSMUSG00000005034	protein kinase, cAMP dependent, catalytic, beta [Acc:MGI:97594]

Rogdi	ENSMUSG00000022540	rogdi homolog (Drosophila) [Acc:MGI:1913299]

Rusc1	ENSMUSG00000041263	RUN and SH3 domain containing 1 [Acc:MGI:1919546]

Scamp5	ENSMUSG00000040722	secretory carrier membrane protein 5 [Acc:MGI:1928948]

Slc25a4	ENSMUSG00000031633	solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), member 4 [Acc:MGI:1353495]

Stx1b2	ENSMUSG00000030806	syntaxin 1B2 [Acc:MGI:1930705]

Sult4a1	ENSMUSG00000018865	sulfotransferase family 4A, member 1 [Acc:MGI:1888971]

Sv2a	ENSMUSG00000038486	synaptic vesicle glycoprotein 2 a [Acc:MGI:1927139]

Syngr3	ENSMUSG00000007021	synaptogyrin 3 [Acc:MGI:1341881]

Tspyl4	ENSMUSG00000039485	TSPY-like 4 [Acc:MGI:106393]

Vamp2	ENSMUSG00000020894	vesicle-associated membrane protein 2 [Acc:MGI:1313277]

Wbp2	ENSMUSG00000034341	WW domain binding protein 2 [Acc:MGI:104709]

Wsb2	ENSMUSG00000029364	WD repeat and SOCS box-containing 2 [Acc:MGI:2144041]

0710005I19Rik	ENSMUSG00000041141	RIKEN cDNA 0710005I19 gene [Acc:MGI:1918941]

2900002G04Rik	ENSMUSG00000041020	RIKEN cDNA 2900002G04 gene [Acc:MGI:1917474]

2900011O08Rik	ENSMUSG00000044117	RIKEN cDNA 2900011O08 gene [Acc:MGI:1914504]

5330410G16Rik	ENSMUSG00000035964	RIKEN cDNA 5330410G16 gene [Acc:MGI:1915187]

A030009H04Rik	ENSMUSG00000043419	RIKEN cDNA A030009H04 gene [Acc:MGI:1915359]


	Contribution of need and non-need factors to the concentration indices for access to MCH care

	Medical treatment for Diarrhea	Skilled birth attendance	Measles immunization	Modern Contraceptive

	Absolute	%	Absolute	%	Absolute	%	Absolute	%

Need factors

Demographic	0.0002	0.1	−0.0079	−1.1	0.0012	1.4	−0.0038	−1.4

Health status	0a	0.0	−0.0072	−1.0	-	-	0.0000	0.0

Subtotal	0.0002	0.1	−0.0151	−2.1	0.0012	1.4	−0.0038	−1.4

Non-need factors

Wealth index	0.0510	33.5	0.1162	15.9	0.0578	68.2	0.1605	58.4

Educational attainment (women)	0.0294	19.3	0.1779	24.4	0.0175	20.7	0.0449	16.4


Generic name	Score	Information from DrugBankb	Information from other sources

Dexamethasone	22.1	An anti-inflammatory 9-fluoro-glucocorticoid.	Dexamethasone was reported to have a dramatic life-saving effect on people with cerebral malaria[44]. However, two subsequent placebo-controlled clinical trials failed to demonstrate clinical benefit[45,46].

Verapamil	21.5	A calcium channel blocker for hypertension, angina, and cluster headache prophylaxis.	A 1995 study[48] reported that verapamil reverses chloroquine resistance in the malaria parasite.

Quercetin	18.9	A flavonol found in plants, antioxidant.	A 2012 study[47] reported that quercetin had antiplasmodial activity.

Miconazole	16.5	An imidazole antifungal agent.	Many studies[39-43] have reported antimalarial activities of antifungal azole compounds.

Clotrimazole	15.9	An imidazole derivative with a broad spectrum of antimycotic activity.	Many studies[39-43] have reported antimalarial activities of azoles, including clotrimazole[43].

Cimetidine	15.5	For acid-reflux disorders (GERD), peptic ulcer disease, heartburn, and acid indigestion.	A 1997 study[49] reported synergism of cimetidine with antimalarial agents. It is ineffective when used alone.

Ketoconazole	15.2	For systemic fungal infections.	Many studies[39-43] have reported antimalarial activities of azoles, including ketoconazole[41].

Nifedipine	14.9	A calcium channel blocker for angina, hypertension, and Raynaud's phenomenon.

Tamoxifen	14.4	For breast cancer.

Clobetasol	14.4	For corticosteroid-responsive dermatoses of the scalp.


		Ethanol (g/L)	Yield (g/g)	Xylose (g/L/h)	Ethanol (g/L/h)	Time (h)

ScF2		52.25 ± 	0.40 ± 0.0	1.10 ±		1


Miracidia1	Mean2	Std. Error	95% CI

Lower	Upper

MweaB. pfeifferix MweaS. mansoni

1 miracidium	7.66	0.80	6.09	9.23

5 miracidia	6.18	0.80	4.61	7.75

10 miracidia	4.04	0.43	3.20	4.88

25 miracidia	4.14	0.55	3.05	5.23

Overall	5.51	0.35	4.83	6.18

MweaB. pfeifferix AsaoS. mansoni

1 miracidium	5.10	0.58	3.96	6.24

5 miracidia	5.34	0.38	4.59	6.09

10 miracidia	3.94	0.26	3.43	4.45

25 miracidia	4.40	0.37	3.68	5.12

Overall	4.70	0.21	4.28	5.11

AsaoB. pfeifferix MweaS. mansoni

1 miracidium	14.42	1.34	11.80	17.04


Variables

During the next 3 months	Measured Scale	Reliability coefficient

Self-efficacy	Very unlikely/very likely	.35a

I would be able to participate regularly in one or more physical activities even if...

 1-I have little free time

 2-I am not carrying excess body weight

Anticipated Regret	Very unlikely/very likely	.80b

During the next 3 months, if I do not participate in one or more physical activities...

 1-This will bother me

 2-I will regret it

 3-I will worry about it

Positive Feeling	Very unlikely/very likely	.52a

If I participate in one or more physical activities...

 1-I will be proud

 2-I would be satisfied

Moral Norm	Strongly disagree/strongly agree	.80b

 1-It is in my principles to participate in one or more physical activities

 2-To participate in one or more physical activities would be acting in accordance with my personal values

 3-It would be against my principles not to participate in one or more physical activities

Descriptive Norm

 1-A lot of people I know participate in one or more physical activities	Strongly disagree/strongly agree	.55a

 2-Among the 5 persons you know best, how many of them participate in one or more physical activities?	0 person to 5 people

Variables

Descriptive Norm

1-A lot of people I know participate in one or more physical activities	Strongly disagree/strongly agree	.55a

2-Among the 5 persons you know best, how many of them participate in one or more physical activities?	0 person to 5 people


Region of location	Upper East (Talensi- Nabdam and Kassena-Nankana West Districts)	Form of involvement (initiation, contribution of partners and management of the collaboration)	Advantages	Disadvantages

Interviews conducted	2 NGO2GHS	- Dubbed “CIMACS”- Initiated by GHS with CRS as an expert partner/and funder.- An MOU signed.- GHS supported with health facilities and personnel.- CRS trained Traditional Birth Attendants (TBAs) and community volunteers in social mobilization skills, provided logistics/incentives to attract pregnant women to deliver in health centres.- Program officers of CRS and focal persons of GHS shared equally in program management and regularly exchanged project progress information.- GHS held review meetings at sub-district, district and regional; quarterly, half yearly and annual basis, to evaluate progress with CRS/stakeholders.- CRS maintained monitoring and evaluation systems e.g. conduct of baseline studies; mid- term and end-of-project evaluations.- Quarterly and annual reports generated and shared with GHS/ donors as a requirement for continued support.- GHS required to keep records of CRS support (material and cash) and to render accounts periodically.	Improvement in maternal and child health indicators-e.g. antenatal registration (25 %); antenatal clinic attendance (22 %); exclusive breastfeeding (25 %); institutional deliveries (55 %); [35] and increased drug and immunization uptake.	- Occasional tendency for some GHS staff to provide somewhat unreliable data not useful for effective programming;- Occasional non-disclosure of full budget lines by GHS- Lack of synchronization of each other’s timetables;- CRS’ eagerness about timelines to demonstrate program performance to donors.

Driver of Collaboration	High under-five and maternal mortality recognized by GHS;- Need to attract pregnant women to deliver in government health centres rather than with TBAs.

Time Frame	2009–2011

Region of location	Upper East (Talensi- Nabdam and Kassena-Nankana West Districts)	Form of involvement (initiation, contribution of partners and management of the collaboration)	Advantages	Disadvantages

Interviews conducted	2 NGO2GHS	- Dubbed “CIMACS”- Initiated by GHS with CRS as an expert partner/and funder.- An MOU signed.- GHS supported with health facilities and personnel.- CRS trained Traditional Birth Attendants (TBAs) and community volunteers in social mobilization skills, provided logistics/incentives to attract pregnant women to deliver in health centres.- Program officers of CRS and focal persons of GHS shared equally in program management and regularly exchanged project progress information.	Improvement in maternal and child health indicators-e.g. antenatal registration (25 %); antenatal clinic attendance (22 %); exclusive b	- Occasional tendency for some GHS staff to provide somewhat unreliable data not useful for effe

Driver of Collaboration	High under-five and maternal mortality recognized by GHS;- Need to attract pregnant women to deliver in government health centres rather than with TBAs.

Tim	2

Region of location	Upper East (Talensi- Nabdam and Kassena-Nankana West Districts)	Form of involvement (initiation, contribution of partners and management of the collaboration)	Advantages	Disadvantages

e Frame	009–2011	- GHS held review meetings at sub-district, district and regional; quarterly, half yearly and annual basis, to evaluate progress with CRS/stakeholders.- CRS maintained monitoring and evaluation systems e.g. conduct of baseline studies; mid- term and end-of-project evaluations.- Quarterly and annual reports generated and shared with GHS/ donors as a requirement for continued support.- GHS required to keep records of CRS support (material and cash) and to render accounts periodically.	reastfeeding (25 %); institutional deliveries (55 %); [35] and increased drug and immunization uptake.	ctive programming;- Occasional non-disclosure of full budget lines by GHS- Lack of synchronization of each other’s timetables;- CRS’ eagerness about timelines to demonstrate program performance to donors.


	Nuevo Laredo	Matamoros	Veracruz

Iowa	Train: 1686 km	Train: 1800 km	Train: 220 kmWater: 2300 km

Ilinois	Train: 1637 km	Train: 1700 km	Train: 405 kmWater: 2300 km

Indiana	Train: 1833 km	Train: 1885 km	Train: 677 kmWater: 2300 km

Total 	1718 km + 650 km to the middle of the country	1795 km + 650 km to the middle of the country	434 km, train + 650 km to the middle of the country, Water: 2300 km

	Nuevo Laredo	Matamoros	Veracruz

Iowa	Train: 1686 km	Train: 1800 km	Train: 220 kmWater: 2300 km

Ilinois	Train: 1637 km	Train: 1700 km	Train: 405 kmWater: 2300 km

Indiana	Train: 18	Train: 1885	Train

	Nuevo Laredo	Matamoros	Veracruz

	33 km	 km	: 677 kmWater: 2300 km

Total	1718 km + 650 km to the middle of the country	1795 km + 650 km to the middle of the country	434 km, train + 650 km to the middle of the country, Water: 2300 km


Model	LnL	AIC	AICc	ΔAICc	AICcWt

Legacy calibrated phylogeny

 Brownian motion single rate	123.77	−229.54	−203.82	221	0.00

 Brownian motion multiple rate	130.51	−219.03	−403.83	20.99	0.00

 Ornstein-Uhlbeck single rate	134.9	−239.91	240.09	664.91	0.00

 Ornstein-Uhlbeck multiple rate	141.01	−240.02	−424.82	0.00	0.99

 Ecological release	125.02	−220.04	259.96	684.78	0.00

 Release and radiate	135.67	−229.34	−414.14	10.68	0.00

 Ecological constraint	119.64	−209.28	270.72	695.54	0.00

 Radiation & ecological constraint	126.43	−210.86	−395.66	30.16	0.00

 Brownian motion/early burst	122.50	−225.01	−188.34	236.48	0.00

 Early burst/Brownian motion	53.24	−86.49	−49.83	374.99	0.00

Isthmus calibrated phylogeny

 Brownian motion single rate	123.94	−229.89	−204.17	223.12	0.00

 Brownian motion multiple rate	131.21	−220.42	−405.22	22.07	0.00

 Ornstein-Uhlbeck single rate	135.1	−240.19	239.81	667.10	0.00

 Ornstein-Uhlbeck multiple rate	142.24	−242.49	−427.29	0.00	0.99

 Ecological release	129.60	−229.20	250.80	678.09	0.00

 Release and radiate	135.48	−228.97	−413.77	13.52	0.00

 Ecological constraint	123.47	−216.94	263.05	690.34	0.00

 Radiation & ecological constraint	125.51	−209.02	−393.82	33.47	0.00

 Brownian motion/early burst	121.06	−222.13	−185.47	241.82	0.00

 Early burst/Brownian motion	121.78	−223.55	−186.89	240.40	0.00


Gene	Target sequence	ShRNA sequences

CXCR4-1	TCCTGGCCTTCATCAGTCT (6)	5′-GAT CCT CCT GGC CTT CAT CAG TCT TTC AAG AGA AGA CTG ATG AAG GCC AGG ATT TTT GGA AGC TAG GA-3′

CXCR4-2	TGCCCACCATCTACTCCAT (7)	5′-GAT CCT GCC CAC CAT CTA CTC CAT TTC AAG AGA ATG GAG TAG ATG GTG GGC ATT TTT GGA AGC TAG CA-3′

Negative control	AATCGCATAGCGTATGCCGTT (8)	5′-GAT CCA ATC GCA TAG CGT ATG CCG TTT TCA AGA GAA ACG GCA TAC GCT ATG CGA TTT TTT TGG AAG CTA GCA-3′

Gene	et sequence	ShRNA sequences

CXCR4-1	TCCTGGCCTTCATCAGTCT (6)	5′-GAT CCT CCT GGC CTT CAT CAG TCT TTC AAG AGA AGA CTG ATG AAG GCC AGG ATT TTT GGA AGC TAG GA-3′

CXCR4-2	TGCCCACCATCTACTCCAT (7)	5′-GAT CCT GCC CAC CAT CTA CTC CAT TTC AAG AGA ATG GAG TAG ATG GTG GGC ATT TTT GGA AGC TAG CA-3′

Negative control	AATCGCATAGCGTATGCCGTT (8)	5′-GAT CCA ATC GCA TAG CGT ATG CCG TTT TCA AGA GAA ACG GCA TAC GCT ATG CGA TTT TTT TGG AAG CTA GCA-3′


Background characteristics	Number (%)

Sex

 Male	86 (7.6)

 Female	975 (86.3)

 Missing	69 (6.1)

Age [mean, (SD)] years	28.8 (SD = 7.5)

Current marital status

 Never married	51 (4.6)

 Married (monogamous)	827 (73.9)

 Married (polygamous)	139 (12.4)

 Othera	102 (9.1)

Education status

 Never in school	166 (14.7)

 Some primary	803 (71.1)

 Above primary	151 (13.3)

 Missing	10 (0.9)

Employment status

 Salaried	778 (68.8)

 Unemployed	213 (18.9)

 Subsistence farmer	70 (6.2)

 Self-employed/wage earners	58 (5.1)

 Missing	11 (1.0)

Relationship to the child

 Parent	1043 (92.3)

 Kin or other	47 (4.2)

 Missing	40 (3.5)

Background characteristics	Number (%)

Never in school	166 (14.7)

Some primary	803 (71.1)

Above primary	151 (13.3)

Missing	10 (0.9)

Employment status

Salaried	778 (68.8)

Unemployed	213 (18.9)

Subsistence farmer	70 (6.2)

Self-employed/wage earners	58 (5.1)

Missing	11 (1.0)

Relationship to the child

Parent	1043 (92.3)

Kin or other	47 (4.2)

Missing	40 (3.5)


VP1 NTa position	NTs in Sabin 2 and cVDPV2 sequences	iVDPV2 sequences	# sequences (iVDPV2) that exhibit variations

32	A	A or C	7

116	A	A or G	1

208	C	A or C	1

218	C	C or T	1

223	T	A or T	12

302	C	A or C	1

307	A	Deletionb	1

358	C	C or T	1

433	G	G or T	12

496	A	A or G	1

502	G	A or G	1

506	A	A or C	1

604	G	A or G	1

740	A	A or G	1

761	C	C or T	1

781	A	A or C or T	11C; 1 T

VP1 NTa position	NTs in Sabin 2 and cVDPV2 sequences	iVDPV2 sequences	# sequences (iVDPV2) that exhibit variations

32	A	A or C	7

116	A	A or G	1

208	C	A or C	1

218	C	C or T	1

223	T	A or T	12

302	C	A or C	1

307	A	Deletionb	1

358	C	C or T	1

433	G	G or T	12

496	A	A or G	1

502	G	A or G	1

506	A	A or C	1

604	G	A or G	1

7		A o

VP1 NTa position	NTs in Sabin 2 and cVDPV2 sequences	iVDPV2 sequences	# sequences (iVDPV2) that exhibit variations

40	A	r G	1

761	C	C or T	1

781	A	A or C or T	11C; 1 T


Description	E7 Clusters*	E14 Clusters*

Affected only by serum	13, 39	13, 39

Affected only by rcSF3	None	None

Serum and rcSF3 oppose one another	7, 14, 18, 34, 35, 38	14, 18, 34, 38

Serum and rcSF3 reinforce one another	0, 8, 49	0, 8, 10, 49

Serum and rcSF3 modulate one another	2, 5, 42	2, 5, 10, 47

Serum and rcSF3 substitute for one another	None	12

Gene expression increases with increasing TER	42	None

Gene expression decreases with increasing TER	None	None

Description	E7 Clusters*	E14 Clusters*

Affected only by rcSF3	None	None

Serum and rcSF3 oppose one another	7, 14, 18, 34, 35, 38	14, 18, 34, 38

Serum and rcSF3 reinforce one another	0, 8, 49	0, 8, 10, 49

Serum and rcSF3 modulate one another	2, 5, 42	2, 5, 10, 47

Serum and rcSF3 substitute for one another	None	12

Gene expression increases with increasing TER	42	None

Gene expression decreases with increasing TER	None	None


Version		Parameter	Separation index	Reliability	Average infit mean square	Average outfit mean square

Malay	9-items	Person ability	2.84	0.89	1.00	1.01

Item difficulty	4.81	0.96	1.00	1.00

7-itemsa	Person ability	2.59	0.87	1.00	0.99

Item difficulty	4.97	0.96	1.00	0.98

Chinese	9-items	Person ability	2.59	0.87	1.00	1.01

Item difficulty	6.96	0.98	1.00	1.02

7-itemsa	Person ability	2.30	0.84	1.01	0.98

Item difficulty	5.28	0.97	1.00	0.98

Version

Malay	9-items

7-itemsa

Chinese	9-items

7-itemsa

Parameter	Separation index	Reliability	Average infit mean square	Average outfit mean square

Person ability	2.84	0.89	1.00	1.01

Item difficulty	4.81	0.96	1.00	1.00

Person ability	2.59	0.87	1.00	0.99

Item difficulty	4.97	0.96	1.00	0.98

Person ability	2.59	0.87	1.00	1.01

Item difficulty	6.96	0.98	1.00	1.02

Person ability	2.30	0.84	1.01	0.98

Item difficulty	5.28	0.97	1.00	0.98


Target	Forward primer	Reverse primer	Product length [bp]	Reference

HPRT	GAGAGCGTTGGGCTTACCTC	ATCGCTAATCACGACGCTGG	136	Rohm et al., 2015

PPARG	GTGCCAGTTTCGATCCGTAGA	GGCCAGCATCGTGTAGATGA	142	Rohm et al., 2015

FAS	CACAGATGATGACAGGAGATGG	TCGGAGTGAGGCTGGGTTGAT	205	Hewitt et al., 2004

LRP2	TGTACCAGAAAATGTGGAAAACC	GTGTCTTCTGTGGCAGTGTAGC	288	Lyons et al., 2003

IGF1R	GGAGTGTCCCTCAGGCTTCA	CATCGCCGCAGACTTTGG	89	Nef et al., 2003

Target	Forward primer	Reverse primer	Product length [bp]	Reference

HPR	GAGAG	AT		Rohm

T	CGTTGGGCTTACCTC	CGCTAATCACGACGCTGG	136	et al., 2015

PPARG	GTGCCAGTTTCGATCCGTAGA	GGCCAGCATCGTGTAGATGA	142	Rohm et al., 2015

FAS	CACAGATGATGACAGGAGATGG	TCGGAGTGAGGCTGGGTTGAT	205	Hewitt et al., 2004

LRP2	TGTACCAGAAAATGTGGAAAACC	GTGTCTTCTGTGGCAGTGTAGC	288	Lyons et al., 2003

IGF1R	GGAGTGTCCCTCAGGCTTCA	CATCGCCGCAGACTTTGG	89	Nef et al., 2003


Study	No. randomized	Characteristics of patients	BMI (SD)	Mean APACHE II score (SD)

LE	HE	LE	HE	LE	HE

Arabi et al. [21]	120	120	>18 years old	28.5 (7.4)	28.5 (8.4)	25.2 (7.5)	25.3 (8.2)

ICU >48 hours

Braunschweig et al. [22]	38	40	>18 years old	30.1 (8.9)	29.8 (9.3)	27.7 (7.9)	23.4 (9.3)

Medical or surgical ICU

ALI <24 hours

Charles et al. [23]	41	42	>18 years old	32.9 (2.0)	28.1 (0.9)	16.6 (0.9)	17.3 (0.8)

Artificial nutrition >48 hours

ICU >48 hours

Desachy et al. [24]	50	50	>18 years old	27 (5)	25 (3)	40 (11)1	42 (17)1

Medical or surgical ICU

Mechanical ventilation >72 hours

Peake et al. [25]	55	57	≥18 years old	26.2 (6.4)	27.8 (7.9)	22 (8.9)	23 (9.1)

Enteral nutrition ≥2 days

Mechanical ventilation

Rice et al. [26]	98	102	ICU admission	29.2 (10.2)	28.2 (9.4)	26.9 (8.1)	26.9 (6.6)

Mechanical ventilation >72 hours

Rice et al. [27]	508	492	ICU admission	29.9 (7.8)	30.4 (8.2)	92 (28)2	90 (27)2

ALI <48 hours

Mechanical ventilation >72 hours

Taylor et al. [28]	41	41	Head injury necessitating mechanical ventilation	N/A	N/A	143	143

Glasgow Coma Scale >3

Rice et al. [26]	98	102	Mechanical ventilation >72 hours	29.2 (10.2)	28.2 (9.4)	26.9 (8.1)	26.9 (6.6)

Rice et al. [27]	508	492	ICU admission	29.9 (7.8)	30.4 (8.2)	92 (28)2	90 (27)2

ALI <48 hours

Mechanical ventilation >72 hours

Taylor et al. [28]	41	41	Head injury necessitating mechanical ventilation	N/A	N/A	143	143

Glasgow Coma Scale >3


Gene name	Primer sequence (5' to 3')	Position in ORF

APN1	3'Race	TGCGCTTCGAAGATTGGCTCACGATA	2018–2044

	5'Race	CTTCGATGAATGCCGAGACGCTGGAC	2122–2097

APN2	3'Race	CTTTGCTGCTGGTGCTATGGAGAACTGG	906–932

	5'Race	ACAGGGCTGACTTCATTTCCGAACCATT	1067–1040

APN3	3'Race	ATGCGTGAYGAYATGTACGGTAT	496–518

	5'Race	GCCAGGAGATAAGTTGACATTTTTGGGG	779–752

APN4	3'Race	TGGCTTTCCATGTGAGCGATTTTGTGC	728–754

	5'Race	CACACCGATTTCTGCAGCATACGAGTGC	849–822

Gene name	Primer sequence (5' to 3')

APN1	3'Race

	5'Race

APN2	3'Race

	5'Race

APN3	3'Race

	5'Race

APN4	3'Race

	5'Race

Primer sequence (5' to 3')	Position in ORF

TGCGCTTCGAAGATTGGCTCACGATA	2018–2044

CTTCGATGAATGCCGAGACGCTGGAC	2122–2097

CTTTGCTGCTGGTGCTATGGAGAACTGG	906–932

ACAGGGCTGACTTCATTTCCGAACCATT	1067–1040

ATGCGTGAYGAYATGTACGGTAT	496–518

GCCAGGAGATAAGTTGACATTTTTGGGG	779–752

TGGCTTTCCATGTGAGCGATTTTGTGC	728–754

CACACCGATTTCTGCAGCATACGAGTGC	849–822


Symbol	Definition	|Fold Change|(TM/TM-MSC)	Padj

MYOC	Myocilin, trabecular meshwork inducible glucocorticoid response	1374	6.97E-04

ANGPTL7	Angiopoietin-like 7	1189	1.48E-03

PCP4	Purkinje cell protein 4	656	2.33E-03

KRT13	Keratin 13	459	1.08E-03

SERPINA3	Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	447	3.75E-03

MYH11	Myosin, heavy chain 11, smooth muscle	429	1.00E-02

CDH23	Cadherin-like 23	420	6.97E-04

HLA-DRA	Major histocompatibility complex, class II, DR alpha	354	9.27E-04

PTGDS	Prostaglandin D2 synthase 21 kDa (Brain)	300	2.05E-02

FAM107A	Family with sequence similarity 107, member A	275	6.97E-04

HBB	Hemoglobin, beta	264	4.13E-03

C2orf40	Chromosome 2 open reading frame 40	239	8.31E-04

FCGBP	Fc fragment of IgG binding protein	231	9.27E-04

APOD	Apolipoprotein D	230	2.40E-02

CXADR	Coxsackie virus and adenovirus receptor	218	7.76E-04

TACSTD2	Tumor-associated calcium signal transducer 2	215	9.45E-04

H19	H19, imprinted maternally expressed transcript (non-protein coding)	210	1.38E-03

KRT5	Keratin 5	209	7.76E-04

CCL3L3	Chemokine (C-C motif) ligand 3-like 3	209	1.27E-03

VCAM1	Vascular cell adhesion molecule 1	199	2.49E-03


Session Topic	Protective Factor Targeted

Introduction and Program OverviewREADY resilience model, protective factors, warning signs of low resilience.

Activity Promotion (group 2 only)Activity benefits, national activity guidelines, step counting & pedometers, identifying preferences, goal setting, barriers & problem solving.	Physical activity

MindfulnessMindfulness vs mindlessness, mindfulness strategies.	Cognitive flexibilityPositive emotions

Defusion 1Thought fusion, identifying unhelpful thoughts, defusion strategies.	Cognitive flexibility

Defusion 2Observer self, defusion strategies.	Cognitive flexibility

AcceptanceAbout emotions, responding to emotions, about acceptance, acceptance strategies.	Positive emotions

Mid Program ReviewResilient and non resilient characteristics, activating and trouble shooting coping strategies.	Active coping

Life Values and Meaningful ActionAbout values, value identification, meaningful action.	Life meaning

Social ConnectednessTypes of support, support responses, active and reflective listening, barriers to social connectedness.	Social support

Relaxation and Pleasant ActivitiesActive relaxation exercises, progressive muscle relaxation exercises, pleasurable activities.	Positive emotions

Review and Planning for the FutureResilient and non resilient characteristics, activating and trouble shooting coping strategies.	Active coping

Session Topic

Introduction and Program OverviewREADY resilience model, protective factors, warning signs of low resilience.

Activity Promotion (group 2 only)Activity benefits, national activity guidelines, step counting & pedometers, identifying preferences, goal setting, barriers & problem solving.

MindfulnessMindfulness vs mindlessness, mindfulness strategies.

Defusion 1Thought fusion, identifying unhelpful thoughts, defusion strategies.

Defusion 2Observer self, defusion strategies.

AcceptanceAbout emotions, responding to emotions, about acceptance, acceptance strategies.

Mid Program ReviewResilient and non resilient characteristics, activating and trouble shooting coping strategies.

Life Values and Meaningful ActionAbout values, value identification, meaningful action.

Social ConnectednessTypes of support, support responses, active and reflective listening, barriers to social connectedness.

Relaxation and Pleasant ActivitiesActive relaxation exercises, progressive muscle relaxation exercises, pleasurable activities.

Review and Planning for the FutureResilient and non resilient characteristics, activating and trouble shooting coping strategies.

Protective Factor Targeted

Physical activity

Cognitive flexibilityPositive emotions

Cognitive flexibility

Cognitive flexibility

Positive emotions

Active coping

Life meaning

Social support

Positive emotions

Active coping


		Three-dimensional scapular attitudes (in degrees)

		Healthy subjects	SIS subjects

				Impaired shoulder		Non-impaired shoulder

Arm Positions	Scapular Rotations	n = 30 shoulders		n = 8 shoulders		n = 8 shoulders

		Mean	SD	Mean	SD	Mean	SD

Rest	A(-) P(+) T	-9.2	4.3	-7.4	3.7	-6.6	4.2

	L(-) M(+) R	-1.1	4.7	-7.6	3.7	-5.3	4.0

	PRO(+) RET(-)	-31.8	5.6	-33.3	6.8	-32.1	5.5

Flexion 70°	A(-) P(+) T	-3.8	4.5	-3.2	3.9	-1.9	5.2

	L(-) M(+) R	-9.3	3.7	-14.5	4.5	-12.4	4.2

	PRO(+) RE	-39.		-40.7	8.2		6

		Three-dimensional scapular attitudes (in degrees)

		Healthy subjects	SIS subjects

				Impaired shoulder		Non-impaired shoulder

Arm Positions	Scapular Rotations	n = 30 shoulders		n = 8 shoulders		n = 8 shoulders

		Mean	SD	Mean	SD	Mean	SD

	T(-)	8	7.5			-39.5	.7

Abduction 90°	A(-) P(+) T	-1.6	5.6	-1.7	5.2	-1.4	7.1

	L(-) M(+) R	-27.5	4.2	-30.4	4.7	-31.6	9.0

	PRO(+) RET(-)	-19.1	6.1	-18.6	8.7	-20.1	6.6


SF-36 Domains	Total Patients (n=308)

Physical Functioning*	67.95 (22.68)

Role Limitation-Physical	53.24 (18.58)

General Health	53.05 (16.96)

Vitality	55.02 (14.93)

Social Functioning	60.11 (20.89)

Role Limitation-Emotional*	55.13 (21.09)

Mental Health	56.91 (16.40)

Bodily Pain*	55.47 (20.96)


Characteristic	Control Group	OC Group	T-Test

Caucasian/NHW	8 (40%)	11 (55%)

African American/Black	1 (5%)	1 (5%)

Hispanic/Latino	5 (25%)	5 (25%)

Asian/Pacific Islander	6 (30%)	3 (15%)


Types	Relative	Personal	DNP	All

EL	6	0	0	6

FL	5	19	6	30

BMB	0	8	0	8

Sum	11	27	6	44


First author [Reference]	Bjerregaard [[28]]	Pelletier [[29]]	Elo [[31]]	Berger [[30]]

Country	Denmark	Canada	Finland	Israel

Year	1991	1998	1979	1990

WB income group	High	High	High	High

Comparators	1. Vaccinate 15-month and 12-yr-olds	1. 1-dose child vaccination campaign	1. Vaccinate 13-yr-olds & post-partum women	1. Vaccinate children from 1 – 12 years

 	2. Vaccinate only 15-month-olds	2. 2-dose child vaccination campaign	2. Vaccinate 13-yr-olds & 1-yr-olds	2. Vaccinate only 12-yr-olds (routine)

 	 	3. 1-dose child vaccination	3. Vaccinate only 1-yr-olds over 20 years

 	 	4. 2-dose child vaccination

Perspective	Societal*	Societal*	Societal*	NR

Cost components measured	OP visits; prescriptions; hospitalizations; vaccines	OP visits; hospitalizations; laboratory tests; nursing home care; special education; indirect costs (lost productivity for illness, disability and premature death)	Fetal loss; fetal damage; annual costs; long-term costs	Vaccine; vaccination side effects; serology; OP visits; hospitalizations; hearing aids; mothers’ work loss;

Method of cost estimation	Micro-costing	Micro-costing; Lifetime earnings (for indirect costs)	Top-down costing based on Delphi panel	Micro-costing

Method of benefits estimation	Averted costs	Averted costs	Averted costs	Averted costs

Time period for costs and benefits	20 years	Lifetime	30 years	13 years

Discounting (Rate)	NR	Yes (5%)	Yes (6%)	Yes (5 and 10%)

Results—Benefit-cost ratio	1. 3	1. 2.6	1. 10	1. 1.1

 	2. 2	2. 2.9	2. 3	2. 1.8

 	 	3. 3.6	3. 6

 	 	4. 4.3

Stated conclusion	Vaccinating both age groups is preferable	The benefits of a second dose outweigh the costs	Vaccinating 13-yr-old girls and postpartum women was preferable	Vaccinating infants and adolescent girls is preferable

Sponsor	NR	LCDC	NR	NR


Organ	OA

Fifth leaf	−0.16 ± 0.07

Awn	0.36 ± 0.07

Lemma	0.42 ± 0.05

Palea	0.30 ± 0.04


	WT 4dpp	KO 4dpp	WT 9dpp	KO 9dpp	WT adult	KO adult

≥2 apoptotic cells per tubule	1.4	3.4	17.6	36.4	28.0	30.5

Total number of tubules counted	300	300	300	300	201	201

Number of testes used	4	4	4	4	2	4

P (Fisher's exact test	0.17		0.0006		0.8

	WT 4dpp	KO 4dpp	WT 9dpp

≥2 apoptotic cells per tubule	1.4	3.4	17.6

Total number of tubules counted	300	300	300

Number of testes used	4	4	4

P (Fisher's exact test	0.17		0.0006


S. No.	Name	Description

1.	Circular Fingerprint	Circular fingerprint is based on CDK’s [31] circular fingerprinter and is functionally equivalent to ECFP-2 [43]

2.	Extended Fingerprint	Functionally equivalent to ExtendedFingerprinter of CDK [31]. This fingerprint is unique from the standard form since it accounts for ring systems. Default length size is 1024 bits.

3.	Substructure Fingerprint	This is a structural key type fingerprint which considers assessment of 307 different substructures and is based on KlekotaRothFingerprinter [44] in CDK.

4.	Enhanced Fingerprint	An in-house developed improvised extended fingerprint which accounts for stereochemistryand charges on molecules.


Elution methods	Elution liquid-solid ratio (mL/g)	Elution time (h)	Elution capacity (Q, mg/g)

Soxhlet extraction	100	24	547

Ultrasonic extraction	40	1	815

Microwave-assisted extraction	40	5	326

Elution methods	Elution liquid-solid ratio (mL/g)	Elution time (h)	Elution capacity (Q, mg/g)

Microwave-assisted extraction	40	5	326


Node	Description	Degree

UBC	ubiquitin C	739

EGFR	epidermal growth factor receptor	157

MDM2	MDM2 proto-oncogene	153

TP53	tumor protein p53	152

APP	amyloid beta precursor protein	149

HSP90AA1	heat shock protein 90 alpha family class A member 1	149

EP300	E1A binding protein p300	135

SUMO1	small ubiquitin-like modifier 1	130

GRB2	growth factor receptor bound protein 2	128

SRC	SRC proto-oncogene, non-receptor tyrosine kinase	126

CTNNB1	catenin beta 1	125

FN1	fibronectin 1	123

YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	122

ESR1	estrogen receptor 1	110

HSP90AB1	heat shock protein 90 alpha family class B member 1	107

HDAC1	histone deacetylase 1	100

AKT1	AKT serine/threonine kinase 1	96

AR	androgen receptor	92

MAPK1	mitogen-activated protein kinase 1	88

CUL7	cullin 7	87

MYC†	v-myc avian myelocytomatosis viral oncogene homolog	87

Node	Description	Degree

UBC	ubiquitin C	739

EGFR	epidermal growth factor receptor	157

MDM2	MDM2 proto-oncogene	153

TP53	tumor protein p53	152

APP	amyloid beta precursor protein	149

HSP90AA1	heat shock protein 90 alpha family class A member 1	149

EP300	E1A binding protein p300	135

SUMO	small ubiquitin-like mod

1	ifier 1	130

GRB2	growth factor receptor bound protein 2	128

SRC	SRC proto-oncogene, non-receptor tyrosine kinase	126

CTNNB1	catenin beta 1	125

FN1	fibronectin 1	123

YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	122

ESR1	estrogen receptor 1	110

HSP90AB1	heat shock protein 90 alpha family class B member 1	107

HDAC1	histone deacetylase 1	100

AKT1	AKT serine/threonine kinase 1	96

AR	androgen receptor	92

MAPK1	mitogen-activated protein kinase 1	88

CUL7	cullin 7	87

MYC†	v-myc avian myelocytomatosis viral oncogene homolog	87


Parameter	Body weight (g)	Food Intake (Kcal)	Glucose (mM)	Ketones (mM)	Seizure Susceptibility

Body weight (g)	1.000

Food Intake (Kcal)	0.488*	1.000

Glucose (mM)	0.509*	0.382*	1.000

Ketones (mM)	-0.379*	-0.379*	-0.429*	1.000

Seizure Susceptibility	0.512*	0.464*	0.616*	-0.510*	1.000

Parameter	Body weight (g)	Food Intake (Kcal)	Glucose (mM)	Ketones (mM)	Seizure Susceptibility

Body weight (g)	1.000

Food Intake (Kcal)	0.488*	1.000

Glu	0.509	0	1


Application	(n) Total	Dead larvae %

(Days)	(Larvae)	CXa (5.5 mg/L)	CX (5.5 mg/L)	CXa (11 mg/L)	CX (11 mg/L)	CXa (22 mg/L)	Control

0	625	–	–	–	–	–	–

3	625	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	24 ± 31,749


Comorbidity	Prevalence

N = 14,005	(n)	(%)	95% CI

Mental health condition	5,401	38.6%	(37.8% to 39.4%)

Physical conditions:

Myocardial infarction	174	1.2%	(1.1% to 1.4%)

Congestive heart disease	233	1.7%	(1.5% to 1.9%)

Chronic obstructive pulmonary disease	1,106	7.9%	(7.5% to 8.3%)

End stage renal disease	223	1.6%	(1.4% to 1.8%)

Peripheral vascular disease	72	0.5%	(0.4% to 0.6%)

Asthma	1,780	12.7%	(12.2% to 13.3%)

Diabetes	1,167	8.3%	(7.9% to 8.8%)

Hypertension	2,093	14.9%	(14.4% to 15.5%)

Stroke	173	1.2%	(1.1% to 1.4%)

At least one physical condition	4820	34.4%	(33.6% to 35.2%)

Physical-mental health multimorbidity	2,174	15.5%	(14.9% to16.1%)

Multimorbidity (at least two physical conditions)	1,508	10.8%	(10.3% to 11.3%)


Phytochemical	Detection system	Observation	Result

Coumarin	365 nm	Blue spot	+

Flavonoids	5% AlCl3	Yellow spot	+

Tannin	2% FeCl3	Greenish Black spot	+

Saponin	10% Vanillin (Ethanol)	Violet and yellow	+

Monoterpene alcohol, Bitter principle saponin	Vanillin-H2SO4	Blue	+

Triterpene and steroid	Lieberman-Buchard’s reagent	Brown and yellow spots	+

Phytochemical	Detection system	Observation	Result

Coumarin	365 nm	Blue spot	+

Flavonoids	5% AlCl3	Yellow spot	+

Tannin	2% FeCl3	Greenish Black spot	+

Sapo	10% Vanillin (Et	Violet and yel

Phytochemical	Detection system	Observation	Result

nin	hanol)	low	+

Monoterpene alcohol, Bitter principle saponin	Vanillin-H2SO4	Blue	+

Triterpene and steroid	Lieberman-Buchard’s reagent	Brown and yellow spots	+


Classification result

Actual result	 Forecast result

P	N

P	TP	FN

N	FP	TN


Time	Predicted value	95% prediction intervals

Lower prediction limit	Upper prediction limit

2013m1	24.68	17.4	31.96


Annotation Clusters	Official Symbol

Vascular development	Eph2, Chd7, Ereg, Foxc1, Gja1, Itgav, Lepr, Nus1, Pdpn,Prox1, S1pr1, Socs3, Zfp36l1

Embryonic morphogenesis	Eph2, Chd7, Chst11, Foxc1, Hes1, Il10, Mmp13, Pbx1,Prox1, Socs3, Spry2, Jag2

Sexual reproduction	Bcl6, Bcl2l11, Crem, Calca, Cadm1, Ereg, Fst, Foxc1,Jag2, Lepr, Pvrl3, Rgs2, Stat3

Response to wounding, Inflammatory and Defense responses	Bmp6, Cd14, Calca, Ddah2, Entpd1, Gja1, Hdac5, Il1f6,Il10, Saa1, Saa2, Stat3, Thbd, Thbs1

Growth factors, GF activity	Areg, Bmp6, Chst11, Csf3, Ereg, Foxc1, Gja1, Hgf, Inhbb,Jag2

DNA binding, Transcription regulation	Arid3b, Bcl6, Bach2, Gata2, Lhx8, Mxd1, Mxi1, Setbp1,Thap2, Crem, Chd7, Dedd2, Foxc1, Hes1, Hdac5, Lrrfip1,Nr4a2, Pbx1, Prox1, Runx2, Stat3, Fosl2, Sbno2, Tshz3, Tle1,Mafb, Zfp36, Zfp36l1

Disulfide bond	Nt53, Abca1, Cd14, Cd80, Edil3, Eph2, Gpr35, Areg,Antxr2, Bmp6, Calca, Cacna1d, Cadm1, Cbln3, CxCr7, Csf3,Entpd1, Ereg, Fst, Gja1, Havcr2, Hgf, Inhbb, Itgav, Il10,Jag2, Lepr, Lifr, Man1a, Mmp13, Mmp3, Mpzl1, Niacr1, Pla1a,Pvrl3, Ptger2, Lpar6, Ramp3, Sema6d, Tnfaip6, Thbd, Thbs1,Trem1, Tnfrsf9

Annotation Clusters	Official Symbol

Response to wounding, Inflammatory and Defense responses	Bmp6, Cd14, Calca, Ddah2, Entpd1, Gja1, Hdac5, Il1f6,Il10, Saa1, Saa2, Stat3, Thbd, Thbs1

Growth factors, GF activity	Areg, Bmp6, Chst11, Csf3, Ereg, Foxc1, Gja1, Hgf, Inhbb,Jag2

DNA binding, Transcription regulation	Arid3b, Bcl6, Bach2, Gata2, Lhx8, Mxd1, Mxi1, Setbp1,Thap2, Crem, Chd7, Dedd2, Foxc1, Hes1, Hdac5, Lrrfip1,Nr4a2, Pbx1, Prox1, Runx2, Stat3, Fosl2, Sbno2, Tshz3, Tle1,Mafb, Zfp36, Zfp36l1

Disulfide bond	Nt53, Abca1, Cd14, Cd80, Edil3, Eph2, Gpr35, Areg,Antxr2, Bmp6, Calca, Cacna1d, Cadm1, Cbln3, CxCr7, Csf3,Entpd1, Ereg, Fst, Gja1, Havcr2, Hgf, Inhbb, Itgav, Il10,Jag2, Lepr, Lifr, Man1a, Mmp13, Mmp3, Mpzl1, Niacr1, Pla1a,Pvrl3, Ptger2, Lpar6, Ramp3, Sema6d, Tnfaip6, Thbd, Thbs1,Trem1, Tnfrsf9


Gene	Ensembl ID	Reference	Sites found by RNA-seq for	Sites found by HTA for	Concordant

exons	junctions	exons	junctions

TP63	ENSG00000073282	Lo Iacono et al. [57]	6	10	2	27	No

TP73	ENSG00000078900	Lo Iacono et al. [57]	0	2	2	6	No

CD44	ENSG00000026508	Wang et al. [58]	34	32	19	43	No

HLA-G	ENSG00000204632	Yan et al. [59]	2	0	0	0	No

POSTN	ENSG00000133110	Morra et al. [60]	3	5	1	7	No

RUNX1	ENSG00000159216	Ito et al. [61]	8	2	18	13	Yes


Field	Code	Character	Item amount	Scores (R)	Calculation method

Physical function	PF	Function	5	3	(Q1 + Q2 + Q3 + Q4 + Q5)/5

Role function	RF	Function	2	3	(Q6 + Q7)/2

Emotional function	EF	Function	4	3	(Q21 + Q22 + Q23 + Q24)/4

Cognitive function	CF	Function	2	3	(Q20+ Q25)/2

Social function	SF	Function	2	3	(Q26 + Q27)/2

Global QOL	QL		2	6	(Q29 + Q30)/2

Fatigue	FA	Symptom	3	3	(Q10 + Q12 + Q26)/3

Nausea and vomiting	NV	Symptom	2	3	(Q14 + Q15)/2

Pain	PA	Symptom	2	3	(Q9 + Q19)/2

Dyspnea	DY	Symptom	1	3	Q8

Sleep disturbance	SL	Symptom	1	3	Q11

Appetite loss	AP	Symptom	1	3	Q13

Constipation	CO	Symptom	1	3	Q16

Diarrhea	DI	Symptom	1	3	Q17

Financial difficulties	FI	Symptom	1	3	Q28

Field	Code	Character	Item amount	Scores (R)	Calculation method

Physical function	PF	Function	5	3	(Q1 + Q2 + Q3 + Q4 + Q5)/5

Role function	RF	Function	2	3	(Q6 + Q7)/2

Emotional function	EF	Function	4	3	(Q21 + Q22 + Q23 + Q24)/4

Cognitive function	CF	Function	2	3	(Q20+ Q25)/2

Social function	SF	Function	2	3	(Q26 + Q27)/2

Global QOL	QL		2	6	(Q29 + Q30)/2

Fatigue	FA	Symptom	3	3	(Q10 + Q12 + Q26)/3

Nausea and vomi	N		2		(Q14

Field	Code	Character	Item amount	Scores (R)	Calculation method

ting	V	Symptom		3	+ Q15)/2

Pain	PA	Symptom	2	3	(Q9 + Q19)/2

Dyspnea	DY	Symptom	1	3	Q8

Sleep disturbance	SL	Symptom	1	3	Q11

Appetite loss	AP	Symptom	1	3	Q13

Constipation	CO	Symptom	1	3	Q16

Diarrhea	DI	Symptom	1	3	Q17

Financial difficulties	FI	Symptom	1	3	Q28


Primer name	Assay	Sequence (5′-3′)	Exon position	Target gene	Amplicon sizes (bp)

GHRL-1 F	RT-PCR	TTTCTGAGCCCTGAACATCAG	1	GHRL	305 canonical (wild-type) preproghrelin

GHRL-4R		GAGAACAGACAGGTGGTTGG	4

GHRL-5OF	RACE	ATGAATGAACACTGCGTTTGCT	N/A	GHRL	174

GHRL-5OR		CAGTTTCTGATGTTCAGGGCTC	1

GHRL-5IF	RACE	GAACACTGCGTTTGCTGGCT	N/A	GHRL	130

GHRL-5IR		GGCCAAGTCCATCCAGAGCA	1

GHRL-2F	qRT-PCR	CTAAGAAGCCGTCAGGCAGACT	2	GHRL (preproghrelin)	153

GHRL-2R		GGGACTGAGCCCCTGACA	3

GHRL1_3F	qRT-PCR	CAGAAACTGCAGTTCAATGC	1 / 3	GHRL (Δex2 preproghrelin)	224

GHRL-4R		CACGTGGTCTCGGAAGTGT	4

GHRL1_4F	qRT-PCR	CTGCAGAAACCCTGGCTGA	1 / 4	GHRL (Δex2,3 preproghrelin)	109

GHRL-4R		CACGTGGTCTCGGAAGTGT	4

GOAT-mF	qRT-PCR	GGTTTCAAGCTCGAGTTGAAGG	N/A	MBOAT4 (GOAT)	212

GOAT-mR		AGTAGGTGAGTTTGAAGAGCCC

GAPDH-F	qRT-PCR	CCTGGAGAAACCTGCCAAGT	N/A	GAPDH	209

GAPDH-R		GCCAAATTCATTGTCGTACCA

GHRL-4R		CACGTGGTCTCGGAAGTGT	4	GHRL (Δex2 preproghrelin)	224

GHRL1_4F	qRT-PCR	CTGCAGAAACCCTGGCTGA	1 / 4	GHRL (Δex2,3 preproghrelin)	109

GHRL-4R		CACGTGGTCTCGGAAGTGT	4

GOAT-mF	qRT-PCR	GGTTTCAAGCTCGAGTTGAAGG	N/A	MBOAT4 (GOAT)	212

GOAT-mR		AGTAGGTGAGTTTGAAGAGCCC

GAPDH-F	qRT-PCR	CCTGGAGAAACCTGCCAAGT	N/A	GAPDH	209

GAPDH-R		GCCAAATTCATTGTCGTACCA


Health Variable	Coefficient (Standard Error)

NR Score	NR Self

Depression	−0.11(0.07)	−0.02(0.06)

Anxiety	−0.08(0.08)	0.05(0.06)

Stress	−0.03(0.07)	0.00(0.00)

Self-reported health	0.26(0.08) ***	−0.15(0.06) *


How did you know when to take your child for his/her most recent immunization?	ChoseResponsec % (95% CI)d	UTD4:3:1:3:3 Chose Response % (95% CI)	UTD4:3:1:3:3 Did Not Chose Response % (95% CI)	UTD 4:3:1:3:3 Difference % points (95% CI)

Otherg	18.3 (16.7, 19.9)	75.4 (71.4, 79.5)	75.0 (72.7, 77.3)	0.4 (-4.3, 5.1)


 	CD8+T cells	CD4+T cells	References

Characteristics	Decreased HBV-specific CD8+ T cells; impaired cytotoxicity (IL-2, IFN-γ and TNF-α); increased inhibitory receptors including PD-1, TIM-3, CTLA-4 and 2B4	Impaired proliferation without obvious defect in Th-1-type cytokines; high PD-1 and low expression of CTLA-4, TIM-3, KLRG1 and 2B4	1, 9, 11, 25, 26, 27, 28, 106, 107

Evidence for immunotherapy	Blockade of the PD-1/PD-L1 pathway restored proliferation and function of HBV-specific CD8+ T cells; blockade of CD244 or its ligand CD48 may recover proliferation, cytokine production and cytotoxicity of exhausted HBV-specific CD8+ T cells; blockade of CTLA-4 was able to increase the proliferation of IFN-γ-producing HBV-specific CD8+ T cells; by blocking Tim-3/galectin-9 interactions, expansion of HBV-specific CD8+ T cells was enhanced, which were able to produce cytokines and mediate cytotoxicity	PDGF-BB inhibited CD4+ T-cell proliferation; antibody specific for the PDGF-B chain was able to reduce the development of liver fibrosis; neutralization of PD-L1/2 was able to improve the ability of CD4+ T cells to produce Th-1 cytokines	11, 26, 35, 47, 49, 51, 61, 62, 63, 106, 107


 	Mucosal Biopsy	Surgical Resection

Actin	Positive	Positive

Vimentin	Positive	Positive

Bcl-2	Positive	Positive

CD138	Positive	Not done

Calponin	Not done	Positive

Collagen type IV	Not done	Pericellular net-like pattern

EMA	Not done	Focal Positive

AE1/3	Negative	Focal Positive

Cam5.2	Negative	Negative

CK20	Negative	Not done

CD56	Negative	Negative

Desmin	Negative	Negative

S100	Negative	Negative

MPO	Negative	Not done

CD20	Negative	Not done

CD21	Negative	Not done

CD99	Negative	Not done

CD30	Negative	Not done

C-Kit	Negative	Negative

DOG1	Negative	Negative

PLAP	Negative	Not done

WT1	Not done	Negative

CD10	Not done	Negative

Chromogranin	Not done	Negative

Synaptophysin	Not done	Patchy Positive

NSE	Not done	Focal Positive

Myogenin	Not done	Negative

EWS translocation	Not done	Negative

SYT translocation	Not done	Negative

CIC-DUX4 translocation	Not done	Negative


Area	Median	Range	Inter Quartile Range (IQR)	Z*	P value

Shenzhen (N = 1,826)	6	0-8	4-7	-12.547	<0.001

Xiuning (N = 2,572)	5	0-8	3-6


Young group	Middle-aged and elderly group


Cell Line	MTT Assay	CellTiter-Glo Assay

MCF10a	ND	ND

MCF-7	24±2	27±2

T47D	26±2	28±3

MDA-MB-231	30±3	30±3

Cell Line	MTT Assay	CellTiter-Glo Assay

MCF10a	ND	ND

MCF-7	24±2	27±2

T47	26±	28


Sno	Sub-District	Health Facility	ANC Attendance	% of Total Attendance	Quota Sampled

Wa Municipality

 1	Kambale Sub	Kambale HC	697	5.64	14

 2	Bamahu Sub	Bamahu HC	407	3.30	8

 3	Charingu Sub	Charingu HC	282	2.28	6

 4	Busa Sub	Busa HC	279	2.26	5

 5	Wa Sub	Wa Reg. Hospital	8942	10.87	180

 6	Wa sub	Wa Central HC	1341	72.50	27

 7	Charia Sub	Dobile CHPS	392	3.18	8

 Total	12,340	100.00	248

Lawra District

 8	Eremon Sub	Eremon HC	107	8.89	19

 9	Lawra Sub	Lawra Dist. Hosp	715	59.43	125

 10	Lawra Sub	Lawra Sub HC	28	2.33	5

 11	Babile Sub	Babile Polyclinic	194	16.13	34

 12	Domwini Sub	Domwini HC	42	3.49	7

 13	Zambo Sub	Zambo HC	117	9.73	20

 Total	1203	100.00	210

Sno	Sub-District	Health Facility	ANC Attendance

Wa Municipality

1	Kambale Sub	Kambale HC	697

2	Bamahu Sub	Bamahu HC	407

3	Charingu Sub	Charingu HC	282

4	Busa Sub	Busa HC	279

5	Wa Sub	Wa Reg. Hospital	8942

6	Wa sub	Wa Central HC	1341

7	Charia Sub	Dobile CHPS	392

Total	12,340

Lawra District

8	Eremon Sub	Eremon HC	107

9	Lawra Sub	Lawra Dist. Hosp	715

10	Lawra Sub	Lawra Sub HC	28

11	Babile Sub	Babile Polyclinic	194

12	Domwini Sub	Domwini HC	42

13	Zambo Sub	Zambo HC	117

Total	1203


Biomarker	Abbreviation	Biological Sample Type	Marker Characteristics

Ethanol	EtOH	BloodUrineBreath	Restricted to conditions where ethanol is still present in circulation.

Ethyl glucuronide /Ethyl sulfate	EtG/EtS	UrineSerumCerebrospinal fluidVitreous humourHairNails	Ethanol metabolite, which remains positive in urine samples 2–5 days after stopping ethanol use. Window of detection dependent on sample type.

Phosphatidylethanol	PEth 	BloodDry blood spots	Ethanol metabolite, which remains detectable 1–2 weeks after alcohol use. Measured by LC-MS or immunological techniques.

Fatty acid ethyl esters	FAEE	PlasmaHairMeconium	Ethanol metabolite derived from a combination of fatty acid with alcohol.

Acetaldehyde adducts and associated immune responses	AA-Ab 	BloodTissue specimens	IgA response towards acetaldehyde adducts most specific for alcohol-related disorders.

Carbohydrate-deficient transferrin	CDT	SerumCerebrospinal fluid	Specific marker of chronic alcohol consumption. Lacks sensitivity for screening purposes.

Gamma-glutamyltransferase	GGT	Serum/plasma	Sensitive marker of alcohol use, liver dysfunction and oxidative stress. Several sources of unspecificity. Normalization time 2–3 weeks.

GGT-CDT combination	GGT-CDT	Serum/plasma	Improves sensitivity and specificity of detecting alcohol abuse. Relies on a mathematical model.

Blood cell counts 		Blood	Mean corpuscular volume (MCV) of erythrocytes typically elevated in alcoholics. Normalization time 2–4 months. Mean corpuscular haemoglobin (MCH) and thrombocytes (platelet counts) are also frequently altered in alcohol abusers. Several sources of unspecificity.

Transaminase enzymes	ALT, AST	Serum/plasma	Suitable for screening for liver dysfunction in alcohol users. Sensitive to effects of excess body weight. AST/ALT ratio increases in alcoholic liver disease.

Biomarker	Abbreviation

Ethanol	EtOH

Ethyl glucuronide /Ethyl sulfate	EtG/EtS

Phosphatidylethanol	PEth

Fatty acid ethyl esters	FAEE

Acetaldehyde adducts and associated immune responses	AA-Ab

Carbohydrate-deficient transferrin	CDT

Gamma-glutamyltransferase	GGT

GGT-CDT combination	GGT-CDT

Blood cell counts

Transaminase enzymes	ALT, AST

Biological Sample Type	Marker Characteristics

BloodUrineBreath	Restricted to conditions where ethanol is still present in circulation.

UrineSerumCerebrospinal fluidVitreous humourHairNails	Ethanol metabolite, which remains positive in urine samples 2–5 days after stopping ethanol use. Window of detection dependent on sample type.

BloodDry blood spots	Ethanol metabolite, which remains detectable 1–2 weeks after alcohol use. Measured by LC-MS or immunological techniques.

PlasmaHairMeconium	Ethanol metabolite derived from a combination of fatty acid with alcohol.

BloodTissue specimens	IgA response towards acetaldehyde adducts most specific for alcohol-related disorders.

SerumCerebrospinal fluid	Specific marker of chronic alcohol consumption. Lacks sensitivity for screening purposes.

Serum/plasma	Sensitive marker of alcohol use, liver dysfunction and oxidative stress. Several sources of unspecificity. Normalization time 2–3 weeks.

Serum/plasma	Improves sensitivity and specificity of detecting alcohol abuse. Relies on a mathematical model.

Blood	Mean corpuscular volume (MCV) of erythrocytes typically elevated in alcoholics. Normalization time 2–4 months. Mean corpuscular haemoglobin (MCH) and thrombocytes (platelet counts) are also frequently altered in alcohol abusers. Several sources of unspecificity.

Serum/plasma	Suitable for screening for liver dysfunction in alcohol users. Sensitive to effects of excess body weight. AST/ALT ratio increases in alcoholic liver disease.


	n	5-year survival rate (%)	P value

Gender			0.759

 Male	1102	52

 Female	479	53

Age (yr)			< 0.001

 ≤ 60	891	58

 >60	690	45

Tumor size (cm)			< 0.001

 ≤ 5	1136	59

 >5	445	36

Tumor location			< 0.001

 Upper third	563	39

 Middle third	275	49

 Lower third	702	65

 Two-third or more	41	32

TNM stage			< 0.001

 Stage I	403	94

 Stage II	382	61

 Stage III	796	27

Type of Gastrectomy			< 0.001

 Subtotal	1342	56

 Total	239	34

Operation time (min)			< 0.001

 < 180	1025	58

 ≥ 180	556	43

Albumin level at admission (g/dl)			0.006

 < 3.5	379	47

 ≥ 3.5	1202	54

Hemoglobin level at admission (g/dl)			< 0.001

 < 12	575	46

 ≥ 12	1006	56

Perioperative blood transfusion			< 0.001

 Yes	298	40

 No	1283	55

	n	5-year survival rate (%)	P value

Male	1102	52

Female	479	53

Age (yr)			< 0.001

≤ 60	891	58

>60	690	45

Tumor size (cm)			< 0.001

≤ 5	1136	59

>5	445	36

Tumor location			< 0.001

Upper third	563	39

Middle third	275	49

Lower third	702	65

Two-third or more	41	32

TNM stage			< 0.001

Stage I	403	94

Stage II	382	61

Stage III	796	27

Type of Gastrectomy			< 0.001

Subtotal	1342	56

Total	239	34

Operation time (min)			< 0.001

< 180	1025	58

≥ 180	556	43

Albumin level at admission (g/dl)			0.006

< 3.5	379	47

≥ 3.5	1202	54

Hemoglobin level at admission (g/dl)			< 0.001

< 12	575	46

≥ 12	1006	56

Perioperative blood transfusion			< 0.001

Yes	298	40

No	1283	55


 	Unstandardized coefficients	Standardized coefficients

Herbs (g/day)	Estimate	Std. error	Estimate	P value

Garlic	0.21	0.03	0.08	0.01

Cinnamon	1.24	0.19	0.08	0.01

Black pepper	0.57	0.15	0.05	0.01

Dried rosemary	3.43	1.17	0.03	0.01

Fresh dill	4.83	2.00	0.03	0.02

Fresh peppermint	−6.77	2.80	−0.03	0.02


Group	Age (years)	Gender	Iris Color*	BMI (kg/m2)	Carotenoid Intake Score	Smoking Status	Years Smoking

StatinUsers	58.05 ± 11.08	n = 13 malesn = 7 females	2.1 ± 0.9	27.51 ± 5.19	14.1 ± 5.25	n = 13 nonsmokersn = 7 past smokersn = 0 current smokers	5.3 ± 9.18

Non-Users	57.95 ± 11.03	n = 14 malesn = 6 females	1.9 ± 0.8	26.34 ± 2.73	13.93 ± 3.63	n = 12 nonsmokersn = 4 past smokersn = 4 current smokers	9.10 ± 12.47

Group	Age (years)	Gender

StatinUsers	58.05 ± 11.08	n = 13 malesn = 7 females

Non-Users	57.95 ± 11.03	n = 14 malesn = 6 females

Iris Color*	BMI (kg/m2)	Carotenoid Intake Score	Smoking Status	Years Smoking

2.1 ± 0.9	27.51 ± 5.19	14.1 ± 5.25	n = 13 nonsmokersn = 7 past smokersn = 0 current smokers	5.3 ± 9.18

1.9 ± 0.8	26.34 ± 2.73	13.93 ± 3.63	n = 12 nonsmokersn = 4 past smokersn = 4 current smokers	9.10 ± 12.47


Items	Test-retest reliability ICC (Confident interval)	Kappa	Weighted kappa	Cronbach’s alpha (Dialysis group)

Symptom/problem	0.997 (0.991-0.999)	0.826-1	0.851-1	0.833

Effects of kidney disease	0.983 (0.951-0.994)	0.75-1	0.828-1	0.794

Burden of kidney disease	1	1-1	1-1	0.651

PCS	0.993 (0.981-0.998)	0.688-1	0.737-1	0.322

MCS	0.996 (0.989-0.999)	0.537


GI transit study (n = 11)	%GE

Nonseptic animals	88.96 ± 8.13

Sham + vehicle + CLP	53.27 ± 10.32

Sham + GTS-21 8 mg/kg + CLP	83.62 ± 5.91*

SPLX + vehicle + CLP	79.49 ± 8.98*

SPLX + GTS-21 8 mg/kg + CLP	77.64 ± 11.81*

Cytokine level in serum (n = 8 to 11)	IL-6

Nonseptic animals	2.57 ± 0.48

Sham + vehicle + CLP	243.56 ± 54.89

Sham + GTS-21 8 mg/kg + CLP	90.26 ± 31.31*

SPLX + vehicle + CLP	74.31 ± 17.45*

SPLX + GTS-21 8 mg/kg + CLP	64.98 ± 7.15*

Cytokine levels in colonic tissue (n = 5 to 11)	IL-6

Nonseptic animals	20.43 ± 4.87

Sham + vehicle + CLP	1281.85 ± 932.10

Sham + GTS-21 8 mg/kg + CLP	134.88 ± 36.15

SPLX + vehicle + CLP	214.22 ± 75.88

SPLX + GTS-21 8 mg/kg + CLP	487.49 ± 343.87


Pairs of raters

PDs	 	Rater TW	% Agreement	 	Rater NW	% Agreement

 	Rater SR	No (N)	Yes (Y)	 	Rater SR	No (N)	Yes (Y)

Avoidant	No (N)	9	0	100	No (N)	7	1	88

 	Yes (Y)	0	1	 	Yes (Y)	0	0

Dependent	N	9	1	90	N	7	0	100

 	Y	0	0	 	Y	0	1

Obsessive-Compulsive	N	8	0	100	N	6	0	100

 	Y	0	2	 	Y	0	2

Passive-aggressive	N	9	0	90	N	6	1	88

 	Y	1	0	 	Y	0	1

Depressive	N	10	0	100	N	7	0	100

 	Y	0	0	 	Y	0	1

Paranoid	N	9	0	90	N	8	0	100

 	Y	1	0	 	Y	0	0

Schizotypal	N	9	0	100	N	8	0	100

 	Y	0	1	 	Y	0	0

Schizoid	N	7	1	90	N	6	0	88

 	Y	0	2	 	Y	1	1

Histrionic	N	10	0	100	N	8	0	100

 	Y	0	0	 	Y	0	0

Narcissistic	N	9	0	100	N	8	0	100

 	Y	0	1	 	Y	0	0

Borderline	N	8	1	90	N	7	0	100

 	Y	0	1	 	Y	0	1

Total Antisocial	N	10	0	100	N	7	0	100

 	Y	0	0	 	Y	0	1

Pairs of raters

	Y	1	0		Y	0	0

Schizotypal	N	9	0	100	N	8	0	100

	Y	0	1		Y	0	0

Schizoid	N	7	1	90	N	6	0	88

	Y	0	2		Y	1	1

Histrionic	N	10	0	100	N	8	0	100

	Y	0	0		Y	0	0

Narcissistic	N	9	0	100	N	8	0	100

	Y	0	1		Y	0	0

Borderline	N	8	1	90	N	7	0	100

	Y	0	1		Y	0	1

Total Antisocial	N	10	0	100	N	7	0	100

	Y	0	0		Y	0	1


Rank	Journal	# citations

1	Journal of the American Chemical Society	351

2	Journal of Organic Chemistry	65

3	Journal of Physical Chemistry A	64

4	Journal of Chemical Physics	58

5	Angewandte Chemie	38

6	Chemical Physics Letters	25

7	Organic Letters	24

8	Tetrahedron Letters	22

8	Journal of Physical Chemistry	22

10	Journal of Computational Chemistry	17

Journal	# citations

Journal of the American Chemical Society	351

Journal of Organic Chemistry	65

Journal of Physical Chemistry A	64

Journal of Chemical Physics	58

Angewandte Chemie	38

Chemical Physics Letters	25

Organic Letters	24

Tetrahedron Letters	22

Journal of Physical Chemistry	22

Journal of Computational Chemistry	17


Study (Author-Date)	Representativeness	Demonstration that outcome not present at outset	Assessment of outcome (proven infection vs suspected infection based on other criteria)	Adequacy of follow-up (<5% loss)

Alleyne 2000 [31]	*	*	*	*

Arabi 2005 [36]	*			*

Bota 2005 [35]	*	*	*	*

Camacho 2011 [8]	*	*		*

Chi 2009 [24]	*	*	*	*

Dasic 2006 [10]	*		*	*

Fichtner 2010 [28]	*	*

Hader 2000 [17]	*	*	*	*

Hoefnagel 2008 [2]	*	*	*

Holloway 1996 [25]			*

Khalil 2005 [9]	*	*	*	*

Kim 2012 [34]	*	*	*	*

Kitchen 2011 [6]			*	*

Lemcke 2012 [20]	*	*	*	*

Leverstein Van-Dall 2010 [21]	*			*

Lo 2007 [18]	*	*		*

Lundberg 2000 [16]	*	*

Lwin 2012 [27]	*		*	*

Lyke 2001 [13]	*	*	*	*

Mahe 1995 [7]	*			*

McLaughlin 2012 [19]				*

Moon 2007 [12]	*		*	*

Park 2004 [29]	*	*	*	*

Rafiq 2011 [15]	*	*	*	*

Rivero-Garvia 2011 [26]	*			*

Roitberg 2001 [30]			*

Scheithauer 2009 [23]	*	*		*

Scheithauer 2010 [22]	*	*		*

Schodel 2012 [32]	*		*	*

Schultz 1993 [11]	*	*	*

Sloffer 2005 [33]		*	*	*

Smigoc 2012 [5]	*	*	*

Smith 1976 [4]	*		*

Williams 2011 [14]	*	*	*	*

Wyler 1972 [3]	*		*	*

Study (Author-Date)	Representativeness	Demonstration that outcome not present at outset	Assessment of outcome (proven infection vs suspected infection based on other criteria)	Adequacy of follow-up (<5% loss)

Kitchen 2011 [6]			*	*

Lemcke 2012 [20]	*	*	*	*

Leverstein Van-Dall 2010 [21]	*			*

Lo 2007 [18]	*	*		*

Lundberg 2000 [16]	*	*

Lwin 2012 [27]	*		*	*

Lyke 2001 [13]	*	*	*	*

Mahe 1995 [7]	*			*

McLaughlin 2012 [19]				*

Moon 2007 [12]	*		*	*

Park 2004 [29]	*	*	*	*

Rafiq 2011 [15]	*	*	*	*

Rivero-Garvia 2011 [26]	*			*

Roitberg 2001 [30]			*

Scheithauer 2009 [23]	*	*		*

Scheithauer 2010 [22]	*	*		*

Schodel 2012 [32]	*		*	*

Schultz 1993 [11]	*	*	*

Sloffer 2005 [33]		*	*	*

Smigoc 2012 [5]	*	*	*

Smith 1976 [4]	*		*

Williams 2011 [14]	*	*	*	*

Wyler 1972 [3]	*		*	*


EU Rarotonga	EU southern group	EU northern group

Village surveyed	No. of people surveyed	% Ag positive	Island surveyed	No. of people surveyed	% Ag positive	Island surveyed	No. of people surveyed	% Ag positive

Tupapa/Maraerenga	200	0.00	Atiu	150	0.00	Pukapuka	200	3.50

Takuvaine/Tutakimoa	200	0.50	Aitutaki	300	7.33	Penrhyn	100	0.00

Ruatonga/A Vaitu	200	0.50	Mauke	150	0.00	Manihiki	100	0.00

Pokoinu/Nikao	200	0.00	Mangaia	200	0.50	Rakahanga	100	2.00

Takitumu	200	0.00	Mitiaro	100	0.00	Suwarrow	2	0.00

Puaikura	200	0.00	–	–	–	–	–	–

Total	1000	0.20	–	900	2.56	–	502	1.79


	HIV-2 infected	HIV-uninfected

	Number died/total per category (%)	Mortality rate per 100 person-years (95% CI)	Number died/total per category (%)	Mortality rate per 100 person-years (95% CI)	Rate ratio (95% CI)


Group	Null model	Full model (OR < 95 % CI)

Individual


Genea	Oedogonium	Stigeoclonium	Scenedesmus	Chlamydomonas

infA	+	-	+	-

petA	-	-	+	+

psaM	+	+	-	-

rpl12	-	-	+	-

rpl32	+	+	-	-

trnL(caa)	+	+	-	-

trnR(ccu)	+	-	-	-

trnR(ucg)	+	-	-	-

trnS(gga)	-	+	-	-


Set A	Set B

CV	AoA	CV	AoA

CHAT	3.80	PIED	3.60	Children + Adults

OEIL	4.10	RUE	5.20	Children + Adults

OEUF	4.50	BOUE	5.80	Children + Adults

BEAU	4.50	PLUIE	4.40	Children + Adults

DOUX	5.10	OIE	5.60	Children + Adults

TRAIN	5.10	JOUR	4.70	Children + Adults

MAIN	3.60	NUIT	4.10	Children + Adults

BRAS	4.20	LOUP	4.70	Children + Adults

DOIGT	3.70	FEU	4.90	Adults

Set A	Set B

CV	AoA	CV

CHAT	3.80	PIED

OEIL	4.10	RUE

OEUF	4.50	BOUE

BEAU	4.50	PLUIE

DOUX	5.10	OIE

TRAIN	5.10	JOUR

MAIN	3.60	NUIT

BRAS	4.20	LOUP

DOIGT	3.70	FEU

Set B

AoA

3.60	Children + Adults

5.20	Children + Adults

5.80	Children + Adults

4.40	Children + Adults

5.60	Children + Adults

4.70	Children + Adults

4.10	Children + Adults

4.70	Children + Adults

4.90	Adults


	Relapse group (n=30)	Remission group (n=35)	P

Withdrawal MPV (fL)	8.0±1.2	8.0±1.0	0.81

Withdrawal TSH (uIU/ml)	1.5±1.0	2.0±1.0	0.03

Withdrawal fT3 (pmol/L)	4.8±1.2	4.7±0.5	0.46

Withdrawal fT4 (pmol/L)	14.8±2.9	13.6±1.6	0.04


Isolates	Identification by API system (% similarity)	Identification by rep-PCR (% identity)

1S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (72.5%)

2S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (80.0%)

3S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (75.8%)

4S	Lactobacillus plantarum (75.9%)	Lactobacillus plantarum (74.6%)

5S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (74.9%)

6S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (74.5%)

7S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (72.6%)

8S	Lactobacillus plantarum (99.9%)	Lactobacillus plantarum (73.0%)

9S	Lactobacillus plantarum (72.0%)	Lactobacillus plantarum (72.9%)

10S	Lactobacillus plantarum (79.0%)	Lactobacillus plantarum (73.9%)

11S	Lactobacillus plantarum (77.0%)	Lactobacillus plantarum (73.6%)

15S	Lactobacillus plantarum (85.9%)	Lactobacillus plantarum (65.8%)

16S	Lactobacillus plantarum (89.9%)	Lactobacillus plantarum (65.7%)

18S	Lactobacillus rhamnosus (97.5%)	Unidentified

19S	Lactobacillus rhamnosus (86.0%)	Unidentified

1K	Lactobacillus rhamnosus (86.0%)	Lactobacillus rhamnosus (73.1%)

3K	Lactobacillus rhamnosus (88.5%)	Lactobacillus rhamnosus (65.0%)

1K1	Lactobacillus rhamnosus (96.5%)	Lactobacillus rhamnosus (70.4%)

2K	Lactobacillus fermentum (74.1%)	Lactobacillus fermentum (69.2%)

13S*	Lactobacillus coprophilus (77.0%)	Lactobacillus fermentum (68.4%)

1SB1	Lactobacillus coprophilus (97.0%)	unidentified


Gene symbol	Forward primer (5′ to 3′)	Reverse primer (5′ to 3′)

Oct-4	CTTGGGCTACACAGGC	CTCAATACTCGTTCGCTTTC

Nanog	TTTGGAAGCTGCTGGGGAAG	GATGGGAGGAGGGGAGAGGA

CDX2	CCGAACAGGGACTTGTTTAGAG	CTCTGGCTTGGATGTTACACAG

TF	ACGCTCCTGCTCGGCTGGGT	CGTCTGCTTCACATCCTTCA

GAPDH	GGAGCCAAAAGGGTCATC	CCAGTGAGTTTCCCGTTC

Gene symbol	Forward primer (5′ to 3′)

Oct-4	CTTGGGCTACACAGGC

Nanog	TTTGGAAGCTGCTGGGGAAG

CDX2	CCGAACAGGGACTTGTTTAGAG

TF	ACGCTCCTGCTCGGCTGGGT

GAPDH	GGAGCCAAAAGGGTCATC

Reverse primer (5′ to 3′)

CTCAATACTCGTTCGCTTTC

GATGGGAGGAGGGGAGAGGA

CTCTGGCTTGGATGTTACACAG

CGTCTGCTTCACATCCTTCA

CCAGTGAGTTTCCCGTTC